BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[MeSH-major] Brachytherapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Endosonography. Esophageal Neoplasms / pathology

[MeSH-minor] Aged. Biopsy, Fine-Needle. Female. Humans. Lymph Nodes / pathology. Lymph Nodes / radiation effects. Lymphatic Metastasis. Neoplasm Recurrence, Local

MedlinePlus Health Information. consumer health - Esophageal Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Gastrointest Endosc. 2005 Nov;62(5):808-10 [16246707.001]

(PMID = 16246706.001).

[ISSN] 0016-5107

[Journal-full-title] Gastrointestinal endoscopy

[ISO-abbreviation] Gastrointest. Endosc.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Epidermotropic Merkel cell carcinoma: a case series with histopathologic examination.

BACKGROUND: Merkel cell carcinoma (MCC), an aggressive malignancy that has been increasing in incidence, rarely presents with an epidermotropic pattern.

In cases 1, 3, and 6, the perinuclear dot pattern observed with cytokeratin-20 in the epidermotropic MCC cells was less pronounced than the pattern observed in the dermis, and in all 6 of the tumors, the epidermal staining pattern observed with epithelial membrane antigen was not more or less prominent than the staining observed in the dermis.

CONCLUSION: The data presented reinforce the differential diagnosis of tumors with an epidermotropic growth pattern and the importance of immunohistochemical staining in the histologic workup of such tumors: squamous cell carcinoma in situ, melanoma, mycosis fungoides, eccrine porocarcinoma, sebaceous carcinoma of the eyelid, mammary and extramammary Paget disease, MCC, and epidermotropic metastases.

It is notable that 3 of 6 identified tumors were located on the eyelid; further study of epidermotropic MCC may shed more light on this finding, either as an unusual coincidence or a finding with unexplained significance.

[MeSH-major] Carcinoma, Merkel Cell / pathology. Eyelid Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

(PMID = 20159312.001).

[ISSN] 1097-6787

[Journal-full-title] Journal of the American Academy of Dermatology

[ISO-abbreviation] J. Am. Acad. Dermatol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Chromogranin A; 0 / Keratin-20

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Most of the head and neck tumors are squamous cell carcinomas (SCCs), which are relatively sensitive to chemotherapeutic agents.

The incident rate of end-stage renal disease is 1.3 times higher in the United States than in Japan.

[MeSH-major] Aging / physiology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / physiopathology. Creatinine / blood. Head and Neck Neoplasms / physiopathology. Kidney Function Tests

MedlinePlus Health Information. consumer health - Creatinine.

MedlinePlus Health Information. consumer health - Head and Neck Cancer.

MedlinePlus Health Information. consumer health - Kidney Tests.

MedlinePlus Health Information. consumer health - Seniors' Health.

Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

Hazardous Substances Data Bank. CARBOPLATIN .

Hazardous Substances Data Bank. FLUOROURACIL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16612154.001).

[ISSN] 0385-0684

[Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy

[ISO-abbreviation] Gan To Kagaku Ryoho

[Language] jpn

[Publication-type] English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] AYI8EX34EU / Creatinine; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil

   

Advertisement

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The chemopreventive and antitumor properties of perillyl alcohol (POH) that were studied preclinically indicate that topical POH inhibits both UVB-induced murine skin carcinogenesis (squamous cell tumor models) and 7,12-dimethylbenz(a)anthracene-induced murine melanoma (transgenic models involving tyrosinase-driven Ras).

There was a borderline reduction in the histopathologic score of the lower-dose POH group compared with the placebo (P = 0.1), but this was not observed in the high-dose group.

No changes were observed in p53 expression, cellular proliferation (by proliferating cell nuclear antigen expression), or apoptosis in either treatment group compared with the placebo group.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Clin Cancer Res. 2000 Feb;6(2):390-6 [10690515.001]

[Cites] Anal Quant Cytol Histol. 2009 Dec;31(6):355-66 [20698351.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1281-6 [11142412.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):573-9 [12050099.001]

[Cites] Gynecol Oncol. 2002 Jun;85(3):464-8 [12051875.001]

[Cites] Int J Gastrointest Cancer. 2002;32(2-3):125-8 [12794248.001]

[Cites] Mol Cancer Res. 2003 Sep;1(11):848-54 [14517347.001]

[Cites] Anal Quant Cytol Histol. 2003 Oct;25(5):285-92 [14603727.001]

[Cites] Int J Pharm. 2004 Jan 28;269(2):373-83 [14706249.001]

[Cites] Clin Cancer Res. 2004 Mar 15;10(6):1875-80 [15041701.001]

[Cites] Cancer Res. 1995 Mar 1;55(5):979-83 [7867007.001]

[Cites] Cancer Res. 1998 Feb 15;58(4):711-6 [9485025.001]

[Cites] J Pharm Biomed Anal. 2005 Mar 9;37(3):447-52 [15740902.001]

[Cites] Anal Quant Cytol Histol. 2007 Apr;29(2):63-70 [17484269.001]

[Cites] Exp Dermatol. 2007 Jun;16(6):490-9 [17518989.001]

[Cites] Cancer Chemother Pharmacol. 2008 Jun;62(1):149-57 [17885756.001]

[Cites] Nutr Cancer. 2008;60(3):325-30 [18444166.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1689-95 [18583468.001]

[Cites] Anal Quant Cytol Histol. 2008 Dec;30(6):316-22 [19160696.001]

[Cites] Breast Cancer Res Treat. 2009 Jun;115(3):661-8 [19125322.001]

[CommentIn] Cancer Prev Res (Phila). 2010 Feb;3(2):132-5 [20103730.001]

(PMID = 20103724.001).

[ISSN] 1940-6215

[Journal-full-title] Cancer prevention research (Philadelphia, Pa.)

[ISO-abbreviation] Cancer Prev Res (Phila)

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P30 CA023074; United States / NCI NIH HHS / CA / P01 CA027502-25; United States / NCI NIH HHS / CA / CA027502; United States / NCI NIH HHS / CA / P30 CA023074-28; United States / NCI NIH HHS / CA / CA023074; United States / NCI NIH HHS / CA / CA027502-25; United States / NCI NIH HHS / CA / P01 CA027502

[Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chromatin; 0 / Monoterpenes; 319R5C7293 / perilla alcohol

[Other-IDs] NLM/ NIHMS161246; NLM/ PMC3270887

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Collision tumour of squamous cell carcinoma and invasive malignant melanoma of scalp - a case report.

[MeSH-major] Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / pathology. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Scalp. Skin Neoplasms / pathology

[MeSH-minor] Aged, 80 and over. Humans. Male. Neoplasm Invasiveness

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

MedlinePlus Health Information. consumer health - Head and Neck Cancer.

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19064339.001).

[ISSN] 1878-0539

[Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS

[ISO-abbreviation] J Plast Reconstr Aesthet Surg

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] Netherlands

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The genome of epithelial tumors is characterized by numerous chromosomal aberrations, DNA base sequence changes, and epigenetic abnormalities.

In squamous cell carcinomas of the lung, CpG methylation patterns undergo substantial changes relative to normal lung epithelium.

Interestingly, a large fraction (almost 80%) of the tumor-specifically methylated sequences are targets of the Polycomb complex in embryonic stem cells.

Homeobox genes are particularly overrepresented and all four HOX gene loci on chromosomes 2, 7, 12, and 17 are hotspots for tumor-associated methylation because of the presence of multiple methylated CpG islands within these loci.

DNA hypomethylation at CpGs in squamous cell tumors preferentially affects repetitive sequence classes including SINEs, LINEs, subtelomeric repeats, and segmental duplications.

Since these epigenetic changes are found in early stage tumors, their contribution to tumor etiology as well as their potential usefulness as diagnostic or prognostic biomarkers of the disease should be considered.

MedlinePlus Health Information. consumer health - Lung Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]

[Cites] Clin Cancer Res. 2004 Apr 1;10(7):2284-8 [15073103.001]

[Cites] Curr Top Dev Biol. 2004;60:55-89 [15094296.001]

[Cites] Chest. 2004 May;125(5 Suppl):90S-4S [15136432.001]

[Cites] Nat Rev Cancer. 2004 Sep;4(9):707-17 [15343277.001]

[Cites] Nature. 2004 Sep 2;431(7004):96-9 [15318244.001]

[Cites] Biochem Biophys Res Commun. 1979 Apr 13;87(3):698-705 [454420.001]

[Cites] Cell. 1980 May;20(1):85-93 [6156004.001]

[Cites] Nature. 1986 May 15-21;321(6067):209-13 [2423876.001]

[Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]

[Cites] Curr Opin Genet Dev. 1993 Apr;3(2):226-31 [8504247.001]

[Cites] Hum Genet. 1993 Jul;91(6):538-46 [8340107.001]

[Cites] Nucleic Acids Res. 1994 Aug 11;22(15):2990-7 [8065911.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2284-9 [9122186.001]

[Cites] J Pharmacol Exp Ther. 2004 Dec;311(3):968-81 [15302897.001]

[Cites] J Biol Chem. 2004 Dec 10;279(50):52456-64 [15456747.001]

[Cites] Histol Histopathol. 2005 Apr;20(2):645-63 [15736067.001]

[Cites] Nat Rev Cancer. 2005 Mar;5(3):223-31 [15719030.001]

[Cites] Mol Biol Cell. 2005 Apr;16(4):1811-22 [15659642.001]

[Cites] Oncogene. 2002 Aug 12;21(35):5400-13 [12154403.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5527-32 [17369352.001]

[Cites] PLoS One. 2007;2(5):e399 [17476321.001]

[Cites] Nat Immunol. 2007 Jun;8(6):584-91 [17468759.001]

[Cites] Nature. 2007 Aug 9;448(7154):714-7 [17687327.001]

[Cites] Nature. 2007 Sep 13;449(7159):248-51 [17713477.001]

[Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]

[Cites] Genome Res. 2008 Jan;18(1):46-59 [18042645.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):252-7 [18162535.001]

[Cites] Oncogene. 2008 Jan 10;27(3):404-8 [17621273.001]

[Cites] Cell. 2008 Jun 27;133(7):1145-8 [18585349.001]

[Cites] Cancer Res. 2008 Dec 15;68(24):10280-9 [19074896.001]

[Cites] Nat Rev Genet. 2007 Apr;8(4):286-98 [17339880.001]

[Cites] Science. 2002 Nov 1;298(5595):1039-43 [12351676.001]

[Cites] Int J Cancer. 2003 Jan 10;103(2):153-60 [12455028.001]

[Cites] Cancer Cell. 2002 Dec;2(6):485-95 [12498717.001]

[Cites] Genomics. 2002 Dec;80(6):621-9 [12504854.001]

[Cites] Cancer Cell. 2003 Jan;3(1):89-95 [12559178.001]

[Cites] Cancer Lett. 2003 Feb 20;190(2):125-33 [12565166.001]

[Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]

[Cites] Mol Cell Biol. 2005 May;25(10):3923-33 [15870267.001]

[Cites] Eur J Cancer. 2005 May;41(8):1223-36 [15911247.001]

[Cites] J Cell Biochem. 2005 Aug 1;95(5):902-17 [15861382.001]

[Cites] Nat Genet. 2005 Aug;37(8):853-62 [16007088.001]

[Cites] Biochem Cell Biol. 2005 Aug;83(4):438-48 [16094447.001]

[Cites] Lab Invest. 2005 Sep;85(9):1172-80 [16025148.001]

[Cites] Nat Methods. 2005 Mar;2(3):219-24 [16163803.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13580-5 [16174748.001]

[Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27 [16204691.001]

[Cites] J Thorac Cardiovasc Surg. 2005 Nov;130(5):1378 [16256792.001]

[Cites] Oncogene. 2005 Nov 3;24(48):7213-23 [16170379.001]

[Cites] Nucleic Acids Res. 2005;33(21):6823-36 [16326863.001]

[Cites] Science. 2006 Jan 20;311(5759):395-8 [16424344.001]

[Cites] Nat Genet. 2006 Feb;38(2):149-53 [16444255.001]

[Cites] Curr Top Microbiol Immunol. 2006;301:259-81 [16570852.001]

[Cites] Cell. 2006 Apr 21;125(2):301-13 [16630818.001]

[Cites] Cancer Res. 2006 Aug 15;66(16):7939-47 [16912168.001]

[Cites] Cancer Res. 2006 Sep 1;66(17):8462-9468 [16951157.001]

[Cites] Cancer Res. 2006 Sep 1;66(17):8469-76 [16951158.001]

[Cites] Nat Genet. 2006 Dec;38(12):1378-85 [17072317.001]

[Cites] Biochim Biophys Acta. 2007 Jan;1775(1):138-62 [17045745.001]

[Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]

[Cites] Nat Genet. 2007 Feb;39(2):157-8 [17200673.001]

[Cites] Nat Genet. 2007 Feb;39(2):237-42 [17211412.001]

[Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]

[Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]

[Cites] Oncogene. 2002 Oct 21;21(48):7435-51 [12379884.001]

[Cites] Crit Rev Oncol Hematol. 1999 Sep;32(1):31-43 [10586353.001]

[Cites] Cell. 1999 Nov 24;99(5):451-4 [10589672.001]

[Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]

[Cites] Clin Cancer Res. 2000 Apr;6(4):1432-8 [10778974.001]

[Cites] Nat Genet. 2000 Jul;25(3):315-9 [10888881.001]

[Cites] Cancer Res. 2001 Jan 1;61(1):249-55 [11196170.001]

[Cites] J Natl Cancer Inst. 2001 May 2;93(9):691-9 [11333291.001]

[Cites] Oncogene. 2001 Jun 14;20(27):3563-7 [11429703.001]

[Cites] Oncogene. 2002 Feb 7;21(7):1048-61 [11850822.001]

[Cites] Oncogene. 2002 May 23;21(23):3804-13 [12032849.001]

[Cites] Nat Genet. 2002 Jun;31(2):141-9 [11992124.001]

[Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]

[Cites] Science. 2003 Apr 18;300(5618):489-92 [12702876.001]

[Cites] Cancer Res. 2003 May 1;63(9):2164-71 [12727835.001]

[Cites] Cancer Res. 2003 Jul 1;63(13):3735-42 [12839967.001]

[Cites] Cancer Sci. 2003 Jul;94(7):589-92 [12841866.001]

[Cites] Development. 2003 Nov;130(21):5083-90 [12944428.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12253-8 [14519846.001]

(PMID = 19429482.001).

[ISSN] 1096-3650

[Journal-full-title] Seminars in cancer biology

[ISO-abbreviation] Semin. Cancer Biol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA084469; None / None / / R21 CA128495-02; United States / NCI NIH HHS / CA / CA084469; United States / NCI NIH HHS / CA / R01 CA084469-09; United States / NCI NIH HHS / CA / CA128495; None / None / / R01 CA084469-09; United States / NCI NIH HHS / CA / R21 CA128495-02; United States / NCI NIH HHS / CA / R21 CA128495

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Polycomb-Group Proteins; 0 / Repressor Proteins

[Number-of-references] 85

[Other-IDs] NLM/ NIHMS96703; NLM/ PMC2680753

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

METHODS: Between July 2001 and April 2004, the Eastern Cooperative Oncology Group (ECOG) conducted a randomized study in which 878 patients with recurrent or advanced non-small-cell lung cancer (stage IIIB or IV) were assigned to chemotherapy with paclitaxel and carboplatin alone (444) or paclitaxel and carboplatin plus bevacizumab (434).

Chemotherapy was administered every 3 weeks for six cycles, and bevacizumab was administered every 3 weeks until disease progression was evident or toxic effects were intolerable.

Patients with squamous-cell tumors, brain metastases, clinically significant hemoptysis, or inadequate organ function or performance status (ECOG performance status, >1) were excluded.

The median progression-free survival in the two groups was 6.2 and 4.5 months, respectively (hazard ratio for disease progression, 0.66; P<0.001), with corresponding response rates of 35% and 15% (P<0.001).

CONCLUSIONS: The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths. (ClinicalTrials.gov number, NCT00021060. )

[MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

[MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Carboplatin / administration & dosage. Carboplatin / adverse effects. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Vascular Endothelial Growth Factor A / blood

Genetic Alliance. consumer health - Lung Cancer.

Genetic Alliance. consumer health - Non-small cell lung cancer.

MedlinePlus Health Information. consumer health - Lung Cancer.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. TAXOL .

Hazardous Substances Data Bank. CARBOPLATIN .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] 2006 Massachusetts Medical Society

[CommentIn] N Engl J Med. 2007 Mar 29;356(13):1373; author reply 1374-5 [17396305.001]

[CommentIn] N Engl J Med. 2007 Mar 29;356(13):1373; author reply 1374-5 [17392310.001]

[CommentIn] N Engl J Med. 2007 Mar 29;356(13):1374; author reply 1374-5 [17396304.001]

[CommentIn] N Engl J Med. 2007 Mar 29;356(13):1373-4; author reply 1374-5 [17396306.001]

[ErratumIn] N Engl J Med. 2007 Jan 18;356(3):318

(PMID = 17167137.001).

[ISSN] 1533-4406

[Journal-full-title] The New England journal of medicine

[ISO-abbreviation] N. Engl. J. Med.

[Language] eng

[Databank-accession-numbers] ClinicalTrials.gov/ NCT00021060

[Grant] United States / NCI NIH HHS / CA / CA12046; United States / NCI NIH HHS / CA / CA14548; United States / NCI NIH HHS / CA / CA16116; United States / NCI NIH HHS / CA / CA21076; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA49957; United States / NCI NIH HHS / CA / CA66636

[Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HPV+ cervical carcinomas and cell lines display altered expression of caspases.

OBJECTIVE: Loss of expression of apoptotic regulatory proteins in many neoplasias might result in defective or delayed apoptosis, thus facilitating tumor growth or survival.

We analyzed here, the basal expression of precursors of apoptotic Caspases in normal cervical epithelium, HPV+ cervical tumor samples and HPV+ tumor-derived cell lines.

METHODS: Expression of initiator and effector Caspases was analyzed by immunochemistry in normal cervical epithelium and three types of cervical tumors (squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma) whereas expression of Caspases in HeLa, SiHa and CaSki cells was by immunofluorescence, Western blot and RT-PCR.

RESULTS: Expression of Caspases 3 and 9 was undetectable in adenocarcinoma and adenosquamous cell carcinoma, respectively.

Whereas in squamous cell carcinoma, the expression of Caspases was similar those observed in normal samples.

Expression of Caspases 3 and 6 was low in HeLa and CaSki cells, while Caspase 8 was low in SiHa and it was not detected in C33-A cells.

We did not observe an effect of the E6/E7 oncogenes on the expression of Caspases in C33-A cell.

CONCLUSION: Our results showed a differential expression of several Caspases in carcinoma samples and cell lines, suggesting multiple alterations of the Caspase pathways in cervical cancer.

[MeSH-major] Caspases / biosynthesis. Papillomavirus Infections / enzymology. Uterine Cervical Neoplasms / enzymology. Uterine Cervical Neoplasms / virology

[MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adenocarcinoma / virology. Blotting, Western. Carcinoma, Adenosquamous / enzymology. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. Cell Line, Tumor. Female. Fluorescent Antibody Technique. HeLa Cells. Human papillomavirus 16. Human papillomavirus 18. Humans. Immunohistochemistry. Isoenzymes / biosynthesis. Paraffin Embedding. Reverse Transcriptase Polymerase Chain Reaction

MedlinePlus Health Information. consumer health - Cervical Cancer.

International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17936882.001).

[ISSN] 1095-6859

[Journal-full-title] Gynecologic oncology

[ISO-abbreviation] Gynecol. Oncol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Isoenzymes; EC 3.4.22.- / Caspases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Oxford experience with neoadjuvant chemotherapy and surgical resection for esophageal adenocarcinomas and squamous cell tumors.

Since February 2000 it has been our practice to offer this chemotherapy regime to patients with T2 and T3 or T1N1 tumors.

Six patients (5.7%) had progressive disease and were inoperable (discovered in four at surgery).

A total of 182 patients with a median age of 63 (range 30-80), 41 squamous and 141 adenocarcinomas underwent surgery.

A radical surgical approach to the primary tumor in combination with OEO2 neoadjuvant chemotherapy has led to a high R0 resection rate and good survival with acceptable morbidity and mortality.

MedlinePlus Health Information. consumer health - Esophageal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18430099.001).

[ISSN] 1442-2050

[Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus

[ISO-abbreviation] Dis. Esophagus

[Language] ENG

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cytokine concentrations in basal cell carcinomas of different histological types and localization.

BACKGROUND: Basal cell carcinoma (BCC) is the most common malignant skin tumor.

Cytokines as major mediators of the immune system have been shown to play an important role in biology of the neoplasm with the general predomination of Th2 cytokines, whereas IFN-?

and other Th1 cytokines are prevalent in spontaneously regressing tumors.

OBJECTIVE: We were interested in comparing cytokine levels in BCC and cutaneous squamous cell tumors with BCC of different localization and histological subtypes.

MATERIAL AND METHODS: Explants from freshly excised BCC from 18 patients, and cutaneous squamous cell tumors (solar keratoses and Bowen's disease) from 9 patients were cultivated for 24 h.

RESULTS: Tissue explants of BCC contained significantly higher concentrations of IL-1beta, IL-4, IL-5, and IL-6 compared to those of squamous cell tumors.

Higher levels of TNF-alpha (p = 0.042), IL-4 (p = 0.028), and IL-5 (p = 0.012) were found in tumors localized to the head and neck compared to those on the trunk or extremities.

Interleukin-6 concentrations were higher in aggressive BCC variants (infiltrative and micronodular), but the difference was not statistically significant (p = 0.068).

CONCLUSIONS: Confirming the earlier findings that BCC is a tumor with a Th2 cytokine microenvironment, this study further shows that BCC situated on the head and neck produce even more of certain Th2 cytokines (IL-4 and IL-5) and TNF-alpha, a crucial immunosuppressive cytokine released upon UVB irradiation.

[MeSH-major] Carcinoma, Basal Cell / chemistry. Cytokines / analysis. Skin Neoplasms / chemistry

[MeSH-minor] Aged. Carcinoma, Squamous Cell / chemistry. Female. Humans. Interleukin-4 / analysis. Interleukin-5 / analysis. Male. Tumor Necrosis Factor-alpha / analysis

MedlinePlus Health Information. consumer health - Skin Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18709290.001).

[ISSN] 1318-4458

[Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica

[ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat

[Language] eng

[Publication-type] Journal Article

[Publication-country] Slovenia

[Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-5; 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Placental site nodule: a tumor-like trophoblastic lesion.

This entity may have bizarre histologic findings and should be distinguished from other aggressive lesions like placental site trophoblastic tumor, epithelioid trophoblastic tumor and squamous cell carcinoma.

[MeSH-major] Gestational Trophoblastic Disease / diagnosis. Placenta Diseases / pathology. Trophoblasts / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19332926.001).

[ISSN] 0974-5130

[Journal-full-title] Indian journal of pathology & microbiology

[ISO-abbreviation] Indian J Pathol Microbiol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] India

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Transliterated title] Fibroxantoma atípico. Estudio clinicopatológico de 10 casos.

INTRODUCTION: Atypical fibroxanthoma (AFX) is a rare tumor of unknown histogenesis, considered by most authorities as a superficial form of malignant fibrous histiocytoma (MFH).

Clinical (age, onset-diagnosis time, location, accompanying pathology, outcome), histological (architectural pattern, cell type, ulceration, vascular or perineural invasion, subcutis involvement, pleomorphism, mitosis, inflammatory infiltrate) and immunohistochemical variable were analyzed.

Pathologically all the cases showed a spindle-cell prevalence arranged in a vaguely storiform pattern, along with both, multinucleated and eosinophilic cells.

Other spindle-cell tumors such as squamous cell carcinoma, malignant melanoma, leyomiosarcoma or dermatofibrosarcoma protuberans must be ruled out by immunohistochemical techniques.

[MeSH-major] Histiocytoma, Benign Fibrous / pathology. Skin Neoplasms / pathology

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16476356.001).

[ISSN] 0001-7310

[Journal-full-title] Actas dermo-sifiliográficas

[ISO-abbreviation] Actas Dermosifiliogr

[Language] spa

[Publication-type] English Abstract; Journal Article

[Publication-country] Spain

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Blacks were more likely to be diagnosed at a more advanced stage and to have squamous cell tumors, but were less likely to undergo surgery.

In multivariate regression controlling for age, sex, marital status, histology, and tumor location, black race was associated with worse survival.

When tumor status, surgery, and radiotherapy were added to the model, race was no longer significantly associated with survival.

While the disparity is due in part to differences in tumor histology, diagnosis at an earlier stage and higher rates of surgery among blacks could reduce this survival disparity.

[MeSH-major] Adenocarcinoma / ethnology. Carcinoma, Squamous Cell / ethnology. Esophageal Neoplasms / ethnology. Esophageal Neoplasms / therapy. Healthcare Disparities

Genetic Alliance. consumer health - Esophageal Cancer.

MedlinePlus Health Information. consumer health - Esophageal Cancer.

MedlinePlus Health Information. consumer health - Health Disparities.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Ann Surg Oncol. 2008 Mar;15(3):674-6 [18095032.001]

(PMID = 17987341.001).

[ISSN] 1534-4681

[Journal-full-title] Annals of surgical oncology

[ISO-abbreviation] Ann. Surg. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Oral malignancies following HSCT: graft versus host disease and other risk factors.

Allogenic hematopoietic stem cell transplantation (HSCT), a procedure that is widely used in the treatment of a large number of malignant and non-malignant hematological diseases, is still associated with a wide range of complications, one of the most important of which is graft versus host disease (GVHD).

The patients undergoing allogenic HSCT are also at high risk of developing secondary neoplasms, particularly leukemias and lymphomas.

Solid tumors are less frequent, and the incidence appears to increase over time; the most frequent solid tumors are squamous cell carcinomas.

They include graft versus host disease (GVHD), preoperative regimens, with either radio-chemotherapy or chemotherapy alone, conditioning regimes, immunosuppressive GVHD prophylaxis, viral infection and chronic stimulation as a result of viral antigens, antigenic stimulation from histocompatibility differences between recipient and donor, primary diagnosis, interaction of any of these factors with genetic predisposition, and other factors such as sex and age.

All patients treated with HSCT should therefore be closely followed over the long term with the aim of identifying the onset of secondary tumors as early as possible.

[MeSH-major] Carcinoma, Squamous Cell / etiology. Graft vs Host Disease / etiology. Hematopoietic Stem Cell Transplantation / adverse effects. Mouth Neoplasms / etiology. Neoplasms, Second Primary / etiology

MedlinePlus Health Information. consumer health - Oral Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16084755.001).

[ISSN] 1368-8375

[Journal-full-title] Oral oncology

[ISO-abbreviation] Oral Oncol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Number-of-references] 39

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] High-resolution mapping of tumor redox status by magnetic resonance imaging using nitroxides as redox-sensitive contrast agents.

The levels of 3CP were examined by EPRI and MRI for differences in reduction between muscle and tumor (squamous cell carcinoma) implanted in the hind leg of C3H mice simultaneously.

The tumor regions exhibited a faster decay rate of the nitroxide compared to muscle (0.097 min(-1) versus 0.067 min(-1), respectively).

[MeSH-major] Magnetic Resonance Imaging / methods. Neoplasms, Experimental / pathology. Nitrogen Oxides / chemistry

[MeSH-minor] Animals. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cyclic N-Oxides / chemistry. Cyclic N-Oxides / metabolism. Electron Spin Resonance Spectroscopy / methods. Female. Mice. Mice, Inbred C3H. Models, Chemical. Muscles / metabolism. Oxidation-Reduction. Pyrrolidines / chemistry. Pyrrolidines / metabolism

MedlinePlus Health Information. consumer health - MRI Scans.

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16638852.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] eng

[Grant] United States / Intramural NIH HHS / / Z01 NS003047-01

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural

[Publication-country] United States

[Chemical-registry-number] 0 / Cyclic N-Oxides; 0 / Nitrogen Oxides; 0 / Pyrrolidines; 14332-28-6 / nitroxyl; 4399-80-8 / 3-carbamoyl-2,2,5,5-tetramethyl-1-pyrrolidinyl-N-oxyl

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pulmonary hypertension due to isolated metastatic squamous cell carcinoma thromboemboli.

The differential diagnosis of pulmonary hypertension due to arterial tumour embolism is often overlooked and deserves contemplation.

This resulted in the surprising definitive diagnosis of thromboembolic pulmonary hypertension secondary to laminated thrombi of metastatic squamous cell tumour emboli.

The site of tumour origin was however not histologically apparent and was unable to be elucidated on extensive further investigation.

[MeSH-major] Arterial Occlusive Diseases / diagnosis. Hypertension, Pulmonary / diagnosis. Neoplasms, Squamous Cell / diagnosis. Pulmonary Embolism / diagnosis. Thromboembolism / diagnosis

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

Genetic Alliance. consumer health - Pulmonary Hypertension.

MedlinePlus Health Information. consumer health - Pulmonary Embolism.

MedlinePlus Health Information. consumer health - Pulmonary Hypertension.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16412689.001).

[ISSN] 1443-9506

[Journal-full-title] Heart, lung & circulation

[ISO-abbreviation] Heart Lung Circ

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Australia

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pemetrexed in advanced non-small-cell lung cancer.

IMPORTANCE OF THE FIELD: Current therapeutic options for advanced non-small-cell lung cancer (NSCLC) yield relatively modest improvements in survival leading to an ongoing search for new active treatment agents.

The efficacy of pemetrexed seems to vary between squamous and nonsquamous histologies.

There is growing evidence that, in patients treated with pemetrexed, nonsquamous tumors have improved outcomes compared to squamous cell tumors.

[MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / therapeutic use. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy

[MeSH-minor] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Humans. Pemetrexed. Survival Rate. Treatment Outcome

Genetic Alliance. consumer health - Lung Cancer.

Genetic Alliance. consumer health - Non-small cell lung cancer.

MedlinePlus Health Information. consumer health - Lung Cancer.

Hazardous Substances Data Bank. PEMETREXED .

Hazardous Substances Data Bank. GUANINE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

SciCrunch. DrugBank: Data: Chemical .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20446853.001).

[ISSN] 1744-7666

[Journal-full-title] Expert opinion on pharmacotherapy

[ISO-abbreviation] Expert Opin Pharmacother

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine

[Number-of-references] 92

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Distribution of Bcl-2 gene expression and its prognostic value in non-small cell lung cancer.

The aim of this study was to determine the expression of Bcl-2 gene and prognostic importance of Bcl-2 expression in paraffin embedded blocks of patients diagnosed with non-small cell lung cancer (NSCLC).

These sections are transferred on to slides covered with poly-L-lysine, then de-paraffinization was made.

Positive staining was observed in 9 (19.6%) patients, but not in 37 (80.4%) patients.

Out of 32 cases with squamous cell tumor, 8 (25%) were observed to have positive staining in their sections, but 24 (75%) were not so.

No staining was observed in 11 cases whose cell type was adenoma and two cases whose cell type was adenosquamos (100%).

Staining was present in the section of one case with large cell (100%).

Median survival time was 36.6 months in cases in which staining was observed and 6.10 months in cases in which staining was not observed, with a significant difference (p< 0.05).

[MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Gene Expression Regulation, Neoplastic. Genes, bcl-2. Lung Neoplasms / genetics. Proto-Oncogene Proteins c-bcl-2 / biosynthesis

[MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

Genetic Alliance. consumer health - Lung Cancer.

Genetic Alliance. consumer health - Non-small cell lung cancer.

MedlinePlus Health Information. consumer health - Lung Cancer.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16456730.001).

[ISSN] 0494-1373

[Journal-full-title] Tüberküloz ve toraks

[ISO-abbreviation] Tuberk Toraks

[Language] eng

[Publication-type] Journal Article

[Publication-country] Turkey

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The cytotoxic activities of these compounds were evaluated against human chronic myeloid leukemia cells (K562) and a human nasopharyngeal epidermoid tumor cell line (KB).

Hazardous Substances Data Bank. GENISTEIN .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17311236.001).

[ISSN] 1612-1880

[Journal-full-title] Chemistry & biodiversity

[ISO-abbreviation] Chem. Biodivers.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Switzerland

[Chemical-registry-number] 0 / Antineoplastic Agents; DH2M523P0H / Genistein

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

RESULTS: Ten tumors were squamous cell carcinoma and one tumor was chondrosarcoma occurring within the radiation field of previous treatment for NPC.

Six tumors were located in the external auditory canal, two in the middle ear cavity, two in the periauricular region and one in the mastoid cavity.

The 3-year disease-free and overall survival rates were 30.3% and 20%, respectively.

[MeSH-major] Carcinoma, Squamous Cell / etiology. Chondrosarcoma / etiology. Ear Neoplasms / etiology. Nasopharyngeal Neoplasms / radiotherapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology

[MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies

Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18948828.001).

[ISSN] 1531-4995

[Journal-full-title] The Laryngoscope

[ISO-abbreviation] Laryngoscope

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Exons 19 and 21 of epidermal growth factor receptor are highly conserved in squamous cell cancer of the head and neck.

EGFR inhibitors might be more effective in patients whose tumors harbor specific EGFR mutations.

The presence of specific EFGR mutations is predictive of over a 75% response rate to TKI therapies as compared to 10% in wild type cases of non-small cell lung cancer.

Design. DNA was extracted from 20 head and neck squamous cell tumors and 4 squamous cell carcinoma cell lines and sequenced the receptor using published primer pairs.

Results. No exon 19 or 21 mutations were found in any of the 20 tumors and 0 of 4 cell lines.

Based on the tumor data we would predict that no greater than 8% of head and neck tumors (CI 97.5%) would be likely to harbor either of these mutations.

Conclusions. Our findings are comparable to results recently published of Korean, Austrian, and Spanish patient populations and we conclude that exon 19 and 21 EGFR mutations are not more common in head and neck cancer than in nonsmall-cell carcinoma.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Cell. 2002 Jun;1(5):413-5 [12124170.001]

[Cites] Tumour Biol. 2007;28(5):273-9 [17962724.001]

[Cites] J Clin Oncol. 2004 Jan 1;22(1):77-85 [14701768.001]

[Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]

[Cites] N Engl J Med. 2005 Feb 24;352(8):786-92 [15728811.001]

[Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]

[Cites] Clin Cancer Res. 2005 Apr 15;11(8):2879-82 [15837736.001]

[Cites] J Urol. 2005 Jun;173(6):1853-62 [15879764.001]

[Cites] Clin Cancer Res. 2005 Dec 1;11(23):8418-24 [16322304.001]

[Cites] Eur J Cancer. 2006 Jan;42(1):109-11 [16324836.001]

[Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]

[Cites] Clin Cancer Res. 2006 Jul 1;12(13):3908-14 [16818686.001]

[Cites] Curr Cancer Drug Targets. 2006 Jun;6(4):333-63 [16848724.001]

[Cites] Cancer Res. 2007 Mar 1;67(5):2325-30 [17332364.001]

[Cites] J Clin Oncol. 2007 Jun 1;25(16):2178-83 [17538162.001]

[Cites] Recent Results Cancer Res. 2007;176:189-99 [17607926.001]

[Cites] J Cell Biochem. 2007 Oct 1;102(2):311-9 [17661350.001]

[Cites] J Clin Oncol. 2003 May 15;21(10):1980-7 [12743152.001]

(PMID = 20130810.001).

[ISSN] 1687-921X

[Journal-full-title] International journal of otolaryngology

[ISO-abbreviation] Int J Otolaryngol

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC2814135

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Transliterated title] Cuidados vocais: questão de prevenção e saúde.

Considering all the patients attended, only one presented malignant neoplasm (squamous cell carcinoma), confirmed later by biopsy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20922288.001).

[ISSN] 1678-4561

[Journal-full-title] Ciência & saúde coletiva

[ISO-abbreviation] Cien Saude Colet

[Language] por

[Publication-type] English Abstract; Journal Article

[Publication-country] Brazil

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

A mass was endoscopically detected in his right posterior oropharyngeal wall, and biopsy revealed a neoplasm consisting of a uniform population of plasma cells.

Computed tomography (CT) showed a broad-based papillary soft tissue density mass projecting into the oropharynx from the right posterior wall of the pharynx, and post-contrast CT showed marked enhancement of the tumor.

The tumor showed slightly higher signal intensity compared with surrounding muscle on MR Tl-weighted images (T1WI) and high signal intensity on MR T2-weighted images (T2WI).

Following radiation therapy, a reduction in tumor size was observed.

Although SEP is a rare tumor, it should be included in the differential diagnosis of tumors of the oropharynx because of its imaging similarities to other, more common malignant tumors, such as squamous cell carcinoma and lymphoma.

[MeSH-major] Oropharyngeal Neoplasms / diagnosis. Plasmacytoma / diagnosis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16555568.001).

[ISSN] 0288-2043

[Journal-full-title] Radiation medicine

[ISO-abbreviation] Radiat Med

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Subglottic tracheal stenosis as primary manifestation of a marginal zone B-cell lymphoma of the larynx.

BACKGROUND: More than 90% of laryngeal tumors are squamous cell carcinomas.

Primary hematopoetic neoplasms of the larynx are rare, being mainly extramedullary plasmocytoma and non-Hodgkin's lymphoma (NHL).

The biopsy revealed the diagnosis of a MALT-type lymphoma (marginal zone B-cell lymphoma).

[MeSH-major] Laryngeal Neoplasms / diagnosis. Lymphoma, B-Cell, Marginal Zone / diagnosis. Tracheal Stenosis / etiology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15875774.001).

[ISSN] 0258-851X

[Journal-full-title] In vivo (Athens, Greece)

[ISO-abbreviation] In Vivo

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Greece

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Metastatic tumor of squamous cell carcinoma from uterine cervix to heart: ante-mortem diagnosis.

The pathological examination revealed metastasis of squamous cells with well-differentiated infiltrative areas.

Four months later, however, she was readmitted to hospital in terminal stage, confirming the guarded prognosis of the disease at this stage.

[MeSH-major] Carcinoma, Squamous Cell / secondary. Heart Neoplasms / secondary. Uterine Cervical Neoplasms / pathology

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

Genetic Alliance. consumer health - Heart tumor.

MedlinePlus Health Information. consumer health - Cervical Cancer.

International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17128293.001).

[ISSN] 1678-4170

[Journal-full-title] Arquivos brasileiros de cardiologia

[ISO-abbreviation] Arq. Bras. Cardiol.

[Language] eng; por

[Publication-type] Case Reports; Journal Article

[Publication-country] Brazil

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The aim of this study was to assess the usefulness of fine needle aspiration cytology (FNAC) as a diagnostic method in lung tumour as well as to determine the incidence of lung cancer in various age and sex group and in relation with smoking.

The most common tumour was squamous cell carcinoma (45%) followed by adenocarcinoma (22%), small cell carcinoma (16%) and large cell carcinoma (8%).

[MeSH-major] Biopsy, Fine-Needle. Lung Neoplasms / diagnosis

[MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / epidemiology. Adult. Age Factors. Aged. Aged, 80 and over. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / epidemiology. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / epidemiology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / epidemiology. Cytodiagnosis. Female. Histocytochemistry. Humans. Male. Middle Aged. Predictive Value of Tests. Risk Factors. Smoking

MedlinePlus Health Information. consumer health - Lung Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17474260.001).

[ISSN] 0377-4929

[Journal-full-title] Indian journal of pathology & microbiology

[ISO-abbreviation] Indian J Pathol Microbiol

[Language] eng

[Publication-type] Journal Article

[Publication-country] India

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer.

Tumor cavitation is frequently noted in these patients, but the clinical significance of this finding has not been fully determined.

Our purposes were to evaluate the frequency, imaging characteristics, and clinical outcome of patients receiving antiangiogenesis agents who develop tumor cavitation, and correlate these findings with therapy related adverse events, especially hemoptysis.

Seventeen patients developed tumor cavitation during the trial (14%; median time to event, 1.8 months; range, 0.7-6.2 months), 16 patients (13%) had preexisting cavitary tumors, and 91 (73%) did not develop cavitation.

Cavity formation was more common with squamous cell histology (p = 0.04) but was not associated with hemoptysis (p = 0.12), tumor location (central versus peripheral), imaging characteristics, progression-free survival (p = 0.56), or overall survival (p = 0.33).

One of five patients with hemoptysis was fatal in a cavitary squamous cell tumor.

CONCLUSION: Development of tumor cavitation is not rare in lung cancer patients treated with antiangiogenesis agents, but the clinical implications are minimal in most cases.

[MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

[MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / blood supply. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / secondary. Adult. Aged. Aged, 80 and over. Carcinoma, Large Cell / blood supply. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate

Genetic Alliance. consumer health - Lung Cancer.

MedlinePlus Health Information. consumer health - Lung Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18379352.001).

[ISSN] 1556-1380

[Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

[ISO-abbreviation] J Thorac Oncol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Angiogenesis Inhibitors

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Squamous cell carcinoma of the lip after allogeneic hemopoietic stem cell transplantation.

Allogeneic hemopoietic stem cell transplantation (HSCT) has been considered a curative treatment option for many hematological and non-hematological disorders.

Despite the use of advanced methods of tissue typing and new therapies, graft versus host disease (GVHD) remains a major obstacle.

Secondary malignancies are also among the most serious long-term complications after HSCT including leukemia, lymphomas, and to a lesser extent, solid tumors.

The most commonly observed solid tumor is squamous cell carcinoma (SCC).

[MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Hematopoietic Stem Cell Transplantation. Lip Neoplasms / pathology. Lip Neoplasms / surgery. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / surgery

[MeSH-minor] Adult. Graft vs Host Disease / pathology. Graft vs Host Disease / surgery. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Male. Multiple Myeloma / pathology. Multiple Myeloma / therapy. Transplantation, Homologous

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

Genetic Alliance. consumer health - Transplantation.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20543542.001).

[ISSN] 1658-3876

[Journal-full-title] Hematology/oncology and stem cell therapy

[ISO-abbreviation] Hematol Oncol Stem Cell Ther

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Saudi Arabia

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In addition, many salivary gland tumors and squamous cell carcinomas had strong D2-40 expression, sometimes making distinction of lymphatics versus tumor edge staining difficult.

D2-40 is excellent for assessing lymphatic invasion in breast, prostate, and cervix as long as the pathologist is aware of the expression in myoepithelial cells/basal cells to avoid misinterpretation of ductal carcinoma in situ or normal prostate glands or tumor stroma retraction as tumor lymphatic invasion.

Given the patchy positivity in basal cells of skin and mucosa and the reactivity in squamous cell carcinoma, D2-40 was not helpful in assessing for microinvasion of squamous cell carcinoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20042851.001).

[ISSN] 1533-4058

[Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM

[ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.

[Language] ENG

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Membrane Glycoproteins; 0 / PDPN protein, human

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Spontaneous and irradiation-induced tumor susceptibility in BRCA2 germline mutant mice and cooperative effects with a p53 germline mutation.

Mutations in both p53 and BRCA2 are commonly seen together in human tumors suggesting that the loss of both genes enhances tumor development.

We found decreased survival and timing of tumor onsets, and significantly higher overall tumor incidences and prevalence of particular tumors, including stomach tumors and squamous cell carcinomas, associated with the homozygous loss of Brca2, independent of p53 status.

The addition of a p53 mutation had a further impact on overall survival, incidence of osteosarcomas and stomach tumors, and tumor latency.

The spectrum of tumors observed for this Brca2 germline mouse model suggest that it faithfully recapitulates some human disease phenotypes associated with BRCA2 loss.

In addition, these findings include extensive in vivo data demonstrating that germline Brca2 and p53 mutations cooperatively affect animal survivals, tumor susceptibilities, and tumor onsets.

[MeSH-major] BRCA2 Protein / genetics. Genes, p53. Germ-Line Mutation. Neoplasms / genetics. Neoplasms, Radiation-Induced / genetics. Radiation, Ionizing

[MeSH-minor] Animals. Bone Neoplasms / genetics. Bone Neoplasms / physiopathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / physiopathology. Female. Gene Expression Regulation, Neoplastic. Genetic Predisposition to Disease. Genotype. Mice. Mice, Inbred C57BL. Mice, Mutant Strains. Osteosarcoma / genetics. Osteosarcoma / physiopathology. Phenotype. Stomach Neoplasms / genetics. Stomach Neoplasms / physiopathology. Survival Rate. Time Factors

Jackson Laboratory JAX®Mice Database. culture/stock collections - 129-Trp53<tm1Tyj>/J (subscription/membership/fee required).

Jackson Laboratory JAX®Mice Database. culture/stock collections - B6.129S2-Trp53<tm1Tyj>/J (subscription/membership/fee required).

Jackson Laboratory JAX®Mice Database. culture/stock collections - B6;129S2-Trp53<tm1Tyj>/J (subscription/membership/fee required).

Jackson Laboratory JAX®Mice Database. culture/stock collections - C.129S2(B6)-Trp53<tm1Tyj>/J (subscription/membership/fee required).

Jackson Laboratory JAX®Mice Database. culture/stock collections - C3Ou.129S2(B6)-Trp53<tm1Tyj>/J (subscription/membership/fee required).

Jackson Laboratory JAX®Mice Database. culture/stock collections - FVB.129S2(B6)-Trp53<tm1Tyj>/J (subscription/membership/fee required).

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16546942.001).

[ISSN] 0192-6233

[Journal-full-title] Toxicologic pathology

[ISO-abbreviation] Toxicol Pathol

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / BRCA2 Protein; 0 / BRCA2 protein, mouse

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Survivin overexpression has been reported in relation to tumor malignancy, suggesting that it is an unfavorable prognostic marker, and antibody responses to this protein have been confirmed in human cancer patients.

The cut-off value for positivity in the anti-survivin ELISA was 0.35, as determined using the mean absorbance +2 S.D. of samples from healthy dogs.

Sera from 16 of 59 (27.1%) cancer and 3 of 25 (12%) non-cancer disease dogs were positive on ELISA.

The highest positivity rates (>50%) among the cancer cases were seen in dogs with mammary tumor, squamous cell carcinoma and melanoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20179386.001).

[ISSN] 0916-7250

[Journal-full-title] The Journal of veterinary medical science

[ISO-abbreviation] J. Vet. Med. Sci.

[Language] ENG

[Publication-type] Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Autoantibodies; 0 / DNA Primers; 0 / Microtubule-Associated Proteins

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Premalignant neoplasms and squamous cell carcinoma of the anal margin.

Understanding anal anatomy and performing a biopsy of any suspicious lesions are essential in avoiding a delay in diagnosis and appropriately treating these tumors.

Combined multimodality treatment has come to play an important role in managing patient with more advanced or metastatic disease.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Dis Colon Rectum. 1997 Aug;40(8):912-8 [9269807.001]

[Cites] J Am Coll Surg. 1997 Nov;185(5):494-505 [9358099.001]

[Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]

[Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]

[Cites] Dis Colon Rectum. 2005 Mar;48(3):444-50 [15747068.001]

[Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]

[Cites] Arch Dermatol. 1999 Jul;135(7):790-3 [10411153.001]

[Cites] Dis Colon Rectum. 1999 Jul;42(7):945-51 [10411443.001]

[Cites] Dis Colon Rectum. 1997 Nov;40(11):1286-93 [9369101.001]

[Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]

[Cites] Ann Surg Oncol. 1997 Sep;4(6):475-80 [9309336.001]

[Cites] Surg Oncol. 1996 Feb;5(1):29-35 [8837302.001]

[Cites] J Am Acad Dermatol. 1992 Dec;27(6 Pt 1):979-82 [1479105.001]

[Cites] Dis Colon Rectum. 1992 May;35(5):422-9 [1568392.001]

[Cites] Lasers Surg Med. 1991;11(4):385-7 [1895869.001]

[Cites] JAMA. 1991 Aug 14;266(6):816-9 [1865520.001]

[Cites] Br J Dermatol. 1988 Aug;119(2):231-40 [3166941.001]

[Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):321-38 [15137960.001]

[Cites] J Surg Oncol. 2004 May 1;86(2):55-62; discussion 63 [15112245.001]

[Cites] Cancer Invest. 2003 Jun;21(3):452-64 [12901291.001]

[Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]

[Cites] Surg Clin North Am. 2002 Dec;82(6):1233-51 [12516851.001]

[Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]

[Cites] Am J Surg. 2001 Apr;181(4):363-5 [11438274.001]

[Cites] Dis Colon Rectum. 2001 Jun;44(6):868-70 [11391150.001]

[Cites] Hematol Oncol Clin North Am. 2001 Apr;15(2):321-44, vi [11370496.001]

[Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]

[Cites] Dis Colon Rectum. 2000 Apr;43(4):499-502 [10789745.001]

[Cites] Br J Surg. 1988 Nov;75(11):1089-92 [2850073.001]

[Cites] Dis Colon Rectum. 1987 Apr;30(4):263-6 [3030676.001]

[Cites] Dis Colon Rectum. 1988 Jun;31(6):419-22 [3288448.001]

[Cites] Dis Colon Rectum. 1988 Apr;31(4):273-8 [3359896.001]

[Cites] JAMA. 1987 Jan 23-30;257(4):516-8 [3795434.001]

[Cites] Dis Colon Rectum. 1983 Nov;26(11):712-5 [6628143.001]

[Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]

[Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):375-88 [15137963.001]

(PMID = 20011315.001).

[ISSN] 1530-9681

[Journal-full-title] Clinics in colon and rectal surgery

[ISO-abbreviation] Clin Colon Rectal Surg

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC2780101

[Keywords] NOTNLM ; Anus neoplasms / Bowen's disease / Paget's disease / squamous cell cancer

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immunolabeling pattern of podoplanin (d2-40) may distinguish basal cell carcinomas from trichoepitheliomas: a clinicopathologic and immunohistochemical study of 49 cases.

When the morphologic distinction between basal cell carcinomas (BCCs) and tichoepitheliomas is unclear, it poses a rare diagnostic challenge as the commonly defined histologic criterion is insufficient for differentiating these two neoplasms from each other.

Their distinction is clinically important because the risk of progressive disease in BCC can be problematic, and trichoepitheliomas misinterpreted as BCC burdens the patient with an inaccurate diagnosis and consequential inappropriate surgery.

Podoplanin (D2-40) is a well-known lymphatic endothelial surface marker that has been postulated to be upregulated in the outer root sheath of hair follicles and cutaneous neoplasms, such as adnexal tumors, squamous cell carcinomas, etc.

We studied the expression of D2-40 by immunohistochemistry to determine if this marker could reliably differentiate these neoplasms from each other.

A total of 49 cutaneous tumors, including 22 cases of trichoepitheliomas and 27 cases of BCC were examined.

This data suggests that D2-40 expression could be a useful potential marker to distinguish BCCs from trichoepitheliomas, especially when there is a high index of histologic suspicion for either of these two tumors.

[MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / diagnosis. Membrane Glycoproteins / biosynthesis. Neoplasms, Basal Cell / diagnosis. Skin Neoplasms / diagnosis

[MeSH-minor] Antibodies, Monoclonal. Antibodies, Monoclonal, Murine-Derived. Diagnosis, Differential. Humans. Immunohistochemistry. Predictive Value of Tests

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20559122.001).

[ISSN] 1533-0311

[Journal-full-title] The American Journal of dermatopathology

[ISO-abbreviation] Am J Dermatopathol

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / PDPN protein, human; 0 / monoclonal antibody D2-40

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Endoscopic submucosal dissection of esophageal squamous cell neoplasms.

BACKGROUND & AIMS: Endoscopic submucosal dissection (ESD) has recently been developed for en bloc resection of stomach neoplasms, which results in high tumor eradication rates as well as a modality for the precise histologic assessment of the entire lesion.

Application of the technique is desirable for esophageal squamous cell neoplasms (SCNs), but there have been no reports on the use of this procedure in the esophagus.

METHODS: An ESD with methods similar to those used for resections of early gastric cancer was performed on 58 consecutive esophageal SCNs with preoperative diagnoses of intraepithelial neoplasm or intramucosal invasive carcinoma occurring in 43 enrolled patients.

RESULTS: The rate of en bloc resection was 100% (58/58), and en bloc resection with tumor-free lateral/basal margins (R0 resection) was 78% (45/58).

Of 40 lesions occurring in 31 patients fulfilling the criteria of node-negative tumors (mean follow-up, 17 months), 1 lesion resected by en bloc resection with nonevaluable tumor-free lateral margins (Rx [lateral] resection) recurred locally 6 months after ESD, which was treated successfully by a second ESD procedure.

[MeSH-major] Esophageal Neoplasms / surgery. Esophagoscopy. Neoplasms, Squamous Cell / surgery

MedlinePlus Health Information. consumer health - Esophageal Cancer.

Hazardous Substances Data Bank. IODINE, ELEMENTAL .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16713746.001).

[ISSN] 1542-3565

[Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

[ISO-abbreviation] Clin. Gastroenterol. Hepatol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Coloring Agents; 9679TC07X4 / Iodine

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

AIMS AND BACKGROUND: To compare conventional fractionation (CF) radiation therapy (RT), arm A, versus a split-course accelerated hyperfractionated schedule (S-AHF), arm B, versus CFRT plus concomitant chemotherapy (CT), arm C, in terms of five-year survival and toxicity for squamous cell tumors of the oropharynx.

Five-year second-tumor-free survival was 85%.

The 13 second tumors were equally distributed and were mainly correlated with tobacco and alcohol consumption (five lung, two esophagus, two oral cavity, one larynx, one pancreas, one hepatocarcinoma, one myeloma).

CONCLUSIONS: The results obtained with the combination of CT and RT compared with RT alone did not reach statistical significance, but combined treatment almost doubled the five-year overall survival, relapse-free survival and locoregional control rate.

Patients with advanced squamous cell carcinomas of the oropharynx who are medically suitable for the combined approach should be treated with a combination of radiotherapy and chemotherapy.

The occurrence of second tumors is relatively common in these patients and may contribute substantially to the causes of death.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy

[MeSH-minor] Aged. Biomarkers, Tumor / analysis. Carboplatin / administration & dosage. Chemotherapy, Adjuvant / adverse effects. Dose Fractionation. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / radiotherapy. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Risk Factors. Salvage Therapy. Survival Analysis. Time Factors. Treatment Failure. Treatment Outcome

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. CARBOPLATIN .

Hazardous Substances Data Bank. FLUOROURACIL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16683383.001).

[ISSN] 0300-8916

[Journal-full-title] Tumori

[ISO-abbreviation] Tumori

[Language] eng

[Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Keratoacanthoma (KA) is a common keratinizing squamous cell neoplasm of unknown origin characterized by rapid growth and spontaneous involution.

Lack of papillomatosis and viral inclusions ruled out the diagnosis of viral wart, absence of granulomatous reaction ruled out deep fungal or mycobacterial infection and lack of cytological atypia and frank architectural abnormalities did not favour a squamous cell carcinoma.

Diagnosis can be challenging as differential diagnoses include pseudoepitheliomatous hyperplasia and squamous cell carcinoma.

[MeSH-minor] Adult. Carcinoma, Squamous Cell / diagnosis. Diagnosis, Differential. Female. Histiocytes / pathology. Humans. Keratinocytes / pathology. Keratins / analysis. Lymphocytes / pathology. Skin Neoplasms / diagnosis

Genetic Alliance. consumer health - Keratoacanthoma.

MedlinePlus Health Information. consumer health - Skin Conditions.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17976209.001).

[ISSN] 1600-0560

[Journal-full-title] Journal of cutaneous pathology

[ISO-abbreviation] J. Cutan. Pathol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Denmark

[Chemical-registry-number] 0 / Coloring Agents; 68238-35-7 / Keratins

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression of human beta-defensins-1, 2 and 4 mRNA in human lung tumor tissue: a pilot study.

AIM: To analyze the patterns of human beta-defensin-1, 2, 4 (hBDs) expression in human lung tumors.

MATERIALS AND METHODS: Tissue samples of surgically resected human lung tumors (squamous cell carcinoma (SCC), n=10; adenocarcinoma (AC), n=10) paired with conditionally normal tissue samples were analyzed for expression of hBD-1, 2, 4 mRNA by semiquantitative RT-PCR.

No correlation was detected between the levels of hBD-1, hBD-2 and hBD-4 mRNA and histological type, differentiation grade of the tumor, and the stage of the disease, as well as the content of hBD-2 peptide in blood serum of lung cancer patients.

CONCLUSION: Human beta-defensins-1 and -2 are often up-regulated in human lung tumors.

[MeSH-major] Gene Expression Regulation, Neoplastic. Lung Neoplasms / metabolism. Up-Regulation. beta-Defensins / biosynthesis

[MeSH-minor] Cell Line, Tumor. Cohort Studies. Humans. Pilot Projects. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tissue Distribution

MedlinePlus Health Information. consumer health - Lung Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18566581.001).

[ISSN] 1812-9269

[Journal-full-title] Experimental oncology

[ISO-abbreviation] Exp. Oncol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Ukraine

[Chemical-registry-number] 0 / DEFB1 protein, human; 0 / DEFB4A protein, human; 0 / RNA, Messenger; 0 / beta-Defensins

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Expression pattern of MAL in normal epithelial cells, benign tumor, and squamous cell carcinoma of larynx].

METHOD: Use the immunohistochemical technique to analyze the distribution of MAL in normal laryngeal epithelial cells, polyp of vocal cords, laryngeal atypical hyperplasia and laryngeal squamous cell carcinoma.

Comparatively, MAL expression is significantly down regulated in laryngeal atypical hyperplasia and laryngeal squamous cell carcinomas (P < 0.05).

MAL, therefore, is a potential marker for early diagnosis of laryngeal squamous cell carcinoma.

[MeSH-major] Carcinoma, Squamous Cell / metabolism. Laryngeal Mucosa / metabolism. Laryngeal Neoplasms / metabolism. Membrane Transport Proteins / metabolism. Myelin Proteins / metabolism. Proteolipids / metabolism

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19670627.001).

[ISSN] 1001-1781

[Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery

[ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / MAL protein, human; 0 / Membrane Transport Proteins; 0 / Myelin Proteins; 0 / Myelin and Lymphocyte-Associated Proteolipid Proteins; 0 / Proteolipids

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition.

PURPOSE: This study aimed to identify molecular determinants of sensitivity of non-small cell lung cancer (NSCLC) to anti-insulin-like growth factor receptor (IGF-IR) therapy.

EXPERIMENTAL DESIGN: A total of 216 tumor samples were investigated, of which 165 consisted of retrospective analyses of banked tissue and an additional 51 were from patients enrolled in a phase II study of figitumumab, a monoclonal antibody against IGF-IR, in stage IIIb/IV NSCLC.

RESULTS: IGF-IR was differentially expressed across histologic subtypes (P = 0.04), with highest levels observed in squamous cell tumors.

Elevated IGF-IR expression was also observed in a small number of squamous cell tumors responding to chemotherapy combined with figitumumab (P = 0.008).

Furthermore, a higher response rate to the combination of chemotherapy and figitumumab was observed in transitional tumors (71%) compared with those in the mesenchymal-like subset (32%; P = 0.03).

Only one epithelial-like tumor was identified in the phase II study, suggesting that advanced NSCLC has undergone significant dedifferentiation at diagnosis.

Genetic Alliance. consumer health - Lung Cancer.

Genetic Alliance. consumer health - Non-small cell lung cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] ©2010 AACR.

[Cites] Appl Immunohistochem Mol Morphol. 2009 Jul;17(4):329-37 [19318915.001]

[Cites] Cancer Lett. 2009 Sep 8;282(1):14-24 [19345478.001]

[Cites] Clin Lung Cancer. 2009 Jul;10(4):281-9 [19632948.001]

[Cites] Mol Cancer Ther. 2009 Aug;8(8):2110-21 [19671761.001]

[Cites] Oncogene. 2009 Aug 27;28(34):3009-21 [19581933.001]

[Cites] Arch Pathol Lab Med. 2009 Sep;133(9):1413-9 [19722747.001]

[Cites] PLoS One. 2009;4(10):e7273 [19806209.001]

[Cites] Endocr Rev. 2009 Oct;30(6):586-623 [19752219.001]

[Cites] J Thorac Oncol. 2009 Nov;4(11):1397-403 [19745765.001]

[Cites] Ann Oncol. 2010 Mar;21(3):562-7 [19767315.001]

[Cites] J Clin Oncol. 2010 May 1;28(13):2174-80 [20351332.001]

[Cites] J Clin Oncol. 2009 May 20;27(15):2516-22 [19380445.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12103-8 [11035789.001]

[Cites] Oncogene. 2001 Aug 16;20(36):4942-50 [11526479.001]

[Cites] J Clin Oncol. 2002 May 15;20(10):2417-28 [12011119.001]

[Cites] Nat Med. 2002 Nov;8(11):1323-7 [12389040.001]

[Cites] Cancer Res. 2002 Nov 1;62(21):6035-8 [12414625.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1413-8 [12433720.001]

[Cites] Int J Cancer. 1994 Mar 15;56(6):858-66 [7509779.001]

[Cites] Clin Cancer Res. 2005 Mar 1;11(5):2063-73 [15756033.001]

[Cites] Ann Oncol. 2006 Jul;17(7):1120-7 [16600976.001]

[Cites] Mol Cell Biol. 2007 Apr;27(8):3165-75 [17296734.001]

[Cites] Int J Cancer. 2008 Feb 1;122(3):572-82 [17955485.001]

[Cites] Breast Cancer Res Treat. 2008 Sep;111(1):79-91 [17902048.001]

[Cites] Nat Rev Cancer. 2008 Dec;8(12):915-28 [19029956.001]

[Cites] J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):415-22 [19030971.001]

[Cites] Cancer Res. 2009 Jan 1;69(1):161-70 [19117999.001]

[Cites] Clin Cancer Res. 2009 Jan 1;15(1):226-37 [19118050.001]

[Cites] Ann Oncol. 2009 May;20(5):842-9 [19153117.001]

[RetractionIn] Clin Cancer Res. 2014 Jun 15;20(12):3358 [24928947.001]

(PMID = 20670944.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] ENG

[Grant] United States / NIEHS NIH HHS / ES / R01 ES015704-04; United States / NCI NIH HHS / CA / P50CA58183; United States / NIEHS NIH HHS / ES / R01 ES015704; United States / NIEHS NIH HHS / ES / ES015704; United States / NCI NIH HHS / CA / P50 CA058183; United States / NCI NIH HHS / CA / R01 CA094118

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Retracted Publication; Validation Studies

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Hormone Antagonists; 0 / Immunoglobulins, Intravenous; 67763-96-6 / Insulin-Like Growth Factor I; VE267FC2UB / figitumumab

[Other-IDs] NLM/ NIHMS226076; NLM/ PMC2952544

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Molecular alterations in nodal metastases and its primary tumors in squamous cell carcinomas of the larynx].

[Transliterated title] Alteraciones moleculares en las metástasis ganglionares y sus tumores primarios en los carcinomas epidermoides de laringe.

INTRODUCTION AND OBJECTIVES: The successive acquisition of molecular alterations determines tumour progression.

During this progression, the development of nodal metastases is one of the most important prognostic factors in laryngeal squamous cell carcinomas.

The aim of this study is to analyze if, in these carcinomas, the molecular alterations in the nodal metastases are different from those present in the primary tumour.

MATERIAL AND METHOD: Paired samples of primary tumour and nodal metastases from 51 patients with squamous cell carcinoma of the supraglottic larynx were studied.

RESULTS: A close correlation in the expression of the proteins studied was observed in the nodal metastases and the corresponding primary tumour, with the exception of HIF-1a expression and the degree of vascularization.

CONCLUSIONS: Most of the molecular alterations in the nodal metastases are already present in the primary tumour, suggesting that these alterations are early events in carcinogenesis.

[MeSH-major] Carcinoma, Squamous Cell / secondary. Laryngeal Neoplasms / pathology

[MeSH-minor] Humans. Immunohistochemistry. Lymphatic Metastasis. Neoplasm Proteins / biosynthesis

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18364203.001).

[ISSN] 0001-6519

[Journal-full-title] Acta otorrinolaringológica española

[ISO-abbreviation] Acta Otorrinolaringol Esp

[Language] spa

[Publication-type] English Abstract; Journal Article

[Publication-country] Spain

[Chemical-registry-number] 0 / Neoplasm Proteins

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We treated a patient with hypopharyngeal fibromatous polyp and speculated the mechanism of this disease.

The greater part of hypopharyngeal tumors is squamous cell carcinomas, and benign tumors are really uncommon.

Fibromatous polyp is not thought to be a true tumor, but the symptoms are almost the same as tumorous diseases, e.g., discomfort in the throat, swallowing difficulty and respiratory distress.

[MeSH-major] Hypopharyngeal Neoplasms / diagnosis. Polyps / diagnosis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16504437.001).

[ISSN] 0385-8146

[Journal-full-title] Auris, nasus, larynx

[ISO-abbreviation] Auris Nasus Larynx

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Netherlands

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.

Many authors have indicated that the presence of an inflammatory response within the tumor may predict not only recurrence and progression but also survival in several tumors, including transitional cell carcinoma (TCC) of the urinary bladder.

The aim of the present study was to define the influence of inflammatory cell infiltrate on recurrence, progression and survival in TCC of the bladder over a long follow-up period.

Between January and December 1995, 410 consecutive patients, who had undergone transurethral or open surgery for bladder tumors at the same urologic center, were selected for the study.

All cases were reviewed to assess histotype, stage and grade of the tumor and presence or absence of tumor-associated inflammatory reaction.

Pathologic evaluation showed superficial TCC in 312 patients, while 98 had an invasive bladder tumor.

Three among 410 bladder tumors were squamous cell carcinomas.

Out of 407 TCCs, 119 (29.23%) presented inflammation within the tumor or the lamina propria.

At 10 years follow-up, a statistically significant association was shown between the presence of inflammation within the tumor or lamina propria and the number of recurrences (p<0.0001).

Moreover, the absence of inflammatory infiltrate in the tumor established the relative risk of suffering more than one recurrence at 2.287 (95% CI 1.180-3.346).

The Mann-Whitney test confirmed a statistically significant difference between superficial bladder tumors with inflammation and those without (26.3 vs 11.5 months, p<0.001).

On multivariate analysis, the presence of inflammation within the tumor was found to be an independent predictor of survival in patients with TCC of the bladder (p=0.027).

Survival analysis by means of the Kaplan-Meier curves showed a statistically significant difference between patients with tumor-associated inflammatory reaction and those without (p=0.0098).

These results confirm that the presence of inflammatory reaction has a good prognostic value in transitional bladder cell carcinoma.

However, to better define its prognostic significance, the characterization of inflammatory cells in tumor-associated tissue reaction must be accomplished.

[MeSH-major] Carcinoma, Transitional Cell / mortality. Carcinoma, Transitional Cell / pathology. Urinary Bladder Neoplasms / mortality. Urinary Bladder Neoplasms / pathology

[MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Inflammation / diagnosis. Inflammation / pathology. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis

Genetic Alliance. consumer health - Transitional cell carcinoma.

MedlinePlus Health Information. consumer health - Bladder Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16820911.001).

[ISSN] 1021-335X

[Journal-full-title] Oncology reports

[ISO-abbreviation] Oncol. Rep.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Greece

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Carcinosarcoma of the oesophagus - a rare mixed type of tumor.

Oesophageal carcinosarcoma is a rare type of oesophageal cancer composed of both squamous cells and sarcomatous cells.

On surgical pathology, it was discovered that the tumor had both squamous cell and sarcomatous cell components, and the final diagnosis was changed to oesophageal carcinosarcoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] © JSCR.

(PMID = 24946341.001).

[ISSN] 2042-8812

[Journal-full-title] Journal of surgical case reports

[ISO-abbreviation] J Surg Case Rep

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Other-IDs] NLM/ PMC3649142

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression of peptidylarginine deiminase type 4 in ovarian tumors.

The current study focused on the expression of PADI4 in various subtypes of ovary cancers, and this study investigated the effects of estrogen on PADI4 expression in SKOV-3 cells that originated from ovary tumors.

We utilized immunohistochemistry, real-time PCR and western blotting to analyze the expression of PADI4 in the tumor tissues and in the cell line that were cultured with estrodial-17β.

PADI4 was detected in serious cystadenocarcinoma (n=39, positivity=100%), clear cell cancer (n=7, positivity= 100%), mucinous cystadenocarcinoma (n=6, positivity=100%), dysgerminoma (n=6, positivity=100%), squamous cell tumor (n=6, positivity=100%), sibnet-ring cell carcinoma (n=6, positivity=100%), endodermal sinus tumor (n=6, positivity=100%), germ cell tumors (n=6, positivity=100%) and immature teratoma (n=6, positivity=100%).

However, PADI4 was either not detected or detected at low levels in granulosa cell tumor (n=6), malignant thecoma (n=6), ovarian cystadenoma (n=5) and normal ovarian tissue (n=11).

PADI4 was evenly distributed in the cytoplasm of tumor cells of serious cystadenocarcinoma that were classified as being grade II and III by histopathological scoring.

However, PADI4 showed granular cellular distribution in the tumor tissues that were isolated from grade I cystadenocarcinoma.

[MeSH-major] Hydrolases / metabolism. Ovarian Neoplasms / enzymology

[MeSH-minor] Blotting, Western. Cell Line, Tumor. Estradiol / pharmacology. Estradiol / physiology. Female. Gene Expression / drug effects. Humans. Immunohistochemistry. Polymerase Chain Reaction. RNA, Messenger / metabolism

MedlinePlus Health Information. consumer health - Ovarian Cancer.

Hazardous Substances Data Bank. ESTRADIOL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Endocr Rev. 1998 Aug;19(4):397-428 [9715373.001]

[Cites] J Biol Chem. 2008 Jul 18;283(29):20060-8 [18499678.001]

[Cites] Int Immunol. 1998 Dec;10(12):1891-5 [9885910.001]

[Cites] Clin Endocrinol (Oxf). 1998 Dec;49(6):695-707 [10209555.001]

[Cites] Rheumatology (Oxford). 2005 Jan;44(1):40-50 [15466895.001]

[Cites] Endocrine. 2005 Apr;26(3):297-300 [16034185.001]

[Cites] BMC Cancer. 2009;9:40 [19183436.001]

[Cites] J Leukoc Biol. 2001 Jul;70(1):46-51 [11435484.001]

[Cites] Biochem Biophys Res Commun. 2002 Jan 25;290(3):979-83 [11798170.001]

[Cites] Oncologist. 2002;7(1):73-81 [11854549.001]

[Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]

[Cites] J Biol Chem. 2002 Dec 20;277(51):49562-8 [12393868.001]

[Cites] J Clin Oncol. 2003 Mar 15;21(6):1180-9 [12637488.001]

[Cites] Ann Rheum Dis. 2004 Apr;63(4):373-81 [15020330.001]

[Cites] Cell. 2004 Sep 3;118(5):545-53 [15339660.001]

[Cites] Science. 2004 Oct 8;306(5694):279-83 [15345777.001]

[Cites] Acta Radiol Oncol. 1980;19(4):241-4 [6257044.001]

[Cites] Cancer Surv. 1994;19-20:287-307 [7895220.001]

[Cites] Am J Epidemiol. 1995 May 1;141(9):828-35 [7717359.001]

[Cites] Mol Carcinog. 2006 Mar;45(3):183-96 [16355400.001]

[Cites] Apoptosis. 2006 Feb;11(2):183-96 [16502257.001]

[Cites] Mol Endocrinol. 2007 Jul;21(7):1617-29 [17456793.001]

[Cites] Hum Reprod Update. 2007 Sep-Oct;13(5):453-63 [17573406.001]

[Cites] Gynecol Oncol. 2007 Nov;107(2):266-73 [17698176.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10746-50 [9724775.001]

(PMID = 20827398.001).

[ISSN] 1449-2288

[Journal-full-title] International journal of biological sciences

[ISO-abbreviation] Int. J. Biol. Sci.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Australia

[Chemical-registry-number] 0 / RNA, Messenger; 4TI98Z838E / Estradiol; EC 3.- / Hydrolases; EC 3.5.3.15 / peptidylarginine deiminase type IV

[Other-IDs] NLM/ PMC2935668

[Keywords] NOTNLM ; Peptidylarginine deiminase type 4 (PADI4/PAD4) / estrodial-17β. / ovarian cancer (OCa)

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Specific subsets include women with peritoneal carcinomatosis, women with isolated axillary lymph node metastases, adenocarcinoma presenting as a single metastatic lesion, young men with features of extragonadal germ cell tumor, squamous carcinoma involving cervical or inguinal lymph nodes, and neuroendocrine carcinoma.

[MeSH-major] Neoplasms, Unknown Primary / therapy

[MeSH-minor] Biomarkers, Tumor / analysis. Humans. Prognosis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19179187.001).

[ISSN] 0093-7754

[Journal-full-title] Seminars in oncology

[ISO-abbreviation] Semin. Oncol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor

[Number-of-references] 58

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Tumor-associated trypsin-2 and matrix metalloprotease-9 (MMP-9) are associated with cancer, particularly with invasive squamous cell carcinomas.

We describe here that oral squamous cell carcinomas express all members of this cascade: MMP-9, trypsin-2 and enterokinase.

The expression of enterokinase in a carcinoma cell line not derived from the duodenum was shown here for the first time.

However, although both proteases were present also in various bone tumor tissues, MMP-9 and trypsin-2 never co-localized at the cellular level in these tissues.

This suggests that the intracellular vesicular co-localization, storage and possible activation of these proteases may be a unique feature for aggressive epithelial tumors, such as squamous cell carcinomas, but not for tumors of mesenchymal origin.

[MeSH-major] Carcinoma, Squamous Cell / enzymology. Enteropeptidase / metabolism. Matrix Metalloproteinase 9 / metabolism. Mouth Neoplasms / enzymology. Trypsin / metabolism. Trypsinogen / metabolism

[MeSH-minor] Bone Neoplasms / enzymology. Carcinoma / enzymology. Cell Line, Tumor. Enzyme Precursors / metabolism. Humans

MedlinePlus Health Information. consumer health - Oral Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18062964.001).

[ISSN] 0014-4827

[Journal-full-title] Experimental cell research

[ISO-abbreviation] Exp. Cell Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Enzyme Precursors; 103964-84-7 / PRSS2 protein, human; 9002-08-8 / Trypsinogen; EC 3.4.21.4 / Trypsin; EC 3.4.21.9 / Enteropeptidase; EC 3.4.24.- / pro-matrix metalloproteinase 9; EC 3.4.24.35 / Matrix Metalloproteinase 9

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The median age was 49.8 years; all but 1 tumor were squamous cell carcinomas.

Ten (83.3%) had pelvic and systemic disease, whereas only 2 had systemic disease alone.

A single patient having metastatic disease in the lung showed stabilization for 6 months to then progressing in bone.

Despite lack of activity of single-agent imatinib, further studies in cervical cancer are deserved to better define the status of imatinib targets in this tumor and to investigate its activity in combination with cytotoxic drugs.

[MeSH-major] Carcinoma, Squamous Cell / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Receptor, Platelet-Derived Growth Factor alpha / metabolism. Uterine Cervical Neoplasms / drug therapy

[MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Benzamides. Chemotherapy, Adjuvant. Female. Humans. Imatinib Mesylate. Middle Aged. Neoplasm Metastasis. Recurrence. Survival Analysis. Treatment Outcome

Genetic Alliance. consumer health - Cervical cancer.

Genetic Alliance. consumer health - Metastatic cancer.

MedlinePlus Health Information. consumer health - Cervical Cancer.

International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

Hazardous Substances Data Bank. IMATINIB MESYLATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19955950.001).

[ISSN] 1525-1438

[Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

[ISO-abbreviation] Int. J. Gynecol. Cancer

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The morphological features of epithelioid sarcoma may closely mimic those of epithelial neoplasms, such as squamous cell carcinoma, mesenchymal tumors, such as benign fibrous histiocytoma, and nonneoplastic lesions, such as granuloma annulare.

Recently, loss of expression of INI1, a tumor suppressor gene/protein, and expression of GLUT-1, a glucose transporter protein, have been described in epithelioid sarcoma.

Twenty-four cases of epithelioid sarcoma, 13 cases of granuloma annulare, 10 cases of rheumatoid nodule, 19 cases of cutaneous squamous cell carcinoma, 7 cases of atypical fibroxanthoma, 9 cases of benign fibrous histiocytoma (dermatofibroma), and 3 cases of nodular fasciitis were immunostained for GLUT-1 and INI1 using commercially available antibodies, heat-induced epitope retrieval, and the Dako Envision detection system.

GLUT-1 was positive in 40%-50% of epithelioid sarcomas, all cases of granuloma annulare and rheumatoid nodules, 67% of benign fibrous histiocytomas, and in all squamous cell carcinomas.

In this clinical context, loss of INI1 expression seems to be an entirely specific marker of epithelioid sarcoma and this finding may be of great value in distinguishing CD34-negative epithelioid sarcoma from squamous cell carcinoma and in the distinction of rare cytokeratin-negative epithelioid sarcomas from necrobiotic processes, nodular fasciitis, and benign fibrous histiocytomas.

In contrast, there does not seem to be a role for GLUT-1 immunohistochemistry in this differential diagnosis.

[MeSH-major] Chromosomal Proteins, Non-Histone / metabolism. DNA-Binding Proteins / metabolism. Glucose Transporter Type 1 / metabolism. Granuloma Annulare / metabolism. Sarcoma / metabolism. Skin Diseases / metabolism. Skin Neoplasms / metabolism. Transcription Factors / metabolism

[MeSH-minor] Biomarkers / metabolism. Diagnosis, Differential. Fasciitis / metabolism. Fasciitis / pathology. Histiocytoma, Benign Fibrous / metabolism. Histiocytoma, Benign Fibrous / pathology. Humans. Neoplasms, Squamous Cell / metabolism. Neoplasms, Squamous Cell / pathology. Rheumatoid Nodule / metabolism. Rheumatoid Nodule / pathology. Xanthomatosis / metabolism. Xanthomatosis / pathology

Genetic Alliance. consumer health - Epithelioid Sarcoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

MedlinePlus Health Information. consumer health - Skin Conditions.

MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19318800.001).

[ISSN] 1533-0311

[Journal-full-title] The American Journal of dermatopathology

[ISO-abbreviation] Am J Dermatopathol

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers; 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / Glucose Transporter Type 1; 0 / SMARCB1 protein, human; 0 / Transcription Factors

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules.

There is often a considerable delay from initial tumour diagnosis to the start of radiotherapy treatment.

This paper extends the calculations of a previous paper on the effects of delays before the initiation of radiotherapy treatment to include results from a variety of practical fractionation regimes for three different types of tumour: squamous cell carcinoma (head and neck), breast and prostate.

The linear quadratic model of radiation effect, logarithmic tumour growth (coupled with delay times where relevant) and the Poisson model for tumour control probability (TCP) are used to calculate the change in TCP for delays between diagnosis and treatment.

The results show that delays in the start of radiotherapy treatment do have an adverse effect on tumour control for fast-growing tumours.

For example, calculations predict a reduction in local tumour control of up to 1.5% per week's delay for head and neck cancers treated following surgery.

In addition, there may be a variety of fractionation regimes that will yield very similar clinical results for each tumour type.

It is shown theoretically that, for the tumour types considered here, it is possible to increase the dose per fraction and decrease the number of fractions while maintaining or increasing TCP relative to standard 2 Gy fractionation regimes, although there may be some advantage to using hyperfractionated regimes for head and neck cancers in order to reduce normal tissue effects.

[MeSH-major] Breast Neoplasms / radiotherapy. Head and Neck Neoplasms / radiotherapy. Prostatic Neoplasms / radiotherapy

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Head and Neck Cancer.

MedlinePlus Health Information. consumer health - Prostate Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18378526.001).

[ISSN] 1748-880X

[Journal-full-title] The British journal of radiology

[ISO-abbreviation] Br J Radiol

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Markers of squamous cell carcinoma in sarco/endoplasmic reticulum Ca2+ ATPase 2 heterozygote mice keratinocytes.

A mutation of Atp2a2 gene encoding the sarco/endoplasmic reticulum Ca(2+)-ATPase 2 (SERCA2) causes Darier's disease in human and null mutation in one copy of Atp2a2 leads to a high incidence of squamous cell tumor in a mouse model.

In SERCA2 heterozygote (SERCA2(+/-)) mice keratinocytes, mechanisms involved in partial depletion of SERCA2 gene and its related tumor induction have not been studied.

Using the gene fishing system, we first found in SERCA2(+/-) keratinocytes that gene level of tumor-associated calcium signal transducer 1, crystalline alphaB, procollagen XVIII alpha1, and nuclear factor I-B were increased.

These results suggest that the alterations of Ca(2+) signaling by SERCA2 haploinsufficiency alternate the gene expression of tumor induction and differentiation in keratinocytes.

[MeSH-major] Carcinoma, Squamous Cell / metabolism. Heterozygote. Keratinocytes / metabolism. Sarcoplasmic Reticulum Calcium-Transporting ATPases / genetics. Sarcoplasmic Reticulum Calcium-Transporting ATPases / metabolism

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Crown Copyright 2009. Published by Elsevier Ltd. All rights reserved.

(PMID = 19840814.001).

[ISSN] 1873-1732

[Journal-full-title] Progress in biophysics and molecular biology

[ISO-abbreviation] Prog. Biophys. Mol. Biol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers; EC 3.6.3.8 / Sarcoplasmic Reticulum Calcium-Transporting ATPases

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Single topical application of AO (0.15-0.3 ml) or isolated sanguinarine (4.5-18 micromol) followed by twice-weekly application of tetradecanoylphorbolmyristate acetate (TPA) for 25 weeks resulted in formation of tumors.

Histopathologically these tumors were of squamous cell carcinoma type and similar to those found in the positive control group using dimethylbenzanthracene (DMBA)/TPA.

Although the genotoxic lesions may be repaired to some extent on withdrawal of consumption of AO contaminated mustard oil and the residual genotoxic effects caused by AO may not be expressed as signs of carcinogenesis.

MedlinePlus Health Information. consumer health - Edema.

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2005 Wiley-Liss, Inc

(PMID = 15981203.001).

[ISSN] 0020-7136

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Alkaloids; 0 / Benzophenanthridines; 0 / Carcinogens; 0 / Isoquinolines; 0 / Plant Oils; 0 / argemone oil; AV9VK043SS / sanguinarine

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

All tumors were squamous cell carcinoma, arising at the glottis in 21 cases and the supraglottis in 12 cases.

Five-year disease-specific survival rates for stage III of glottic cancer, stage IV of glottic cancer, stage III of supraglottic cancer, and stage IV of supraglottic cancer were 100%, 56.3%, 100%, and 28.1%, respectively.

Both of them died of disease despite undergoing chemotherapy.

[MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / therapy

Genetic Alliance. consumer health - Laryngeal cancer.

Genetic Alliance. consumer health - TEN.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20879822.001).

[ISSN] 0365-5237

[Journal-full-title] Acta oto-laryngologica. Supplementum

[ISO-abbreviation] Acta Otolaryngol Suppl

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

DESIGN: Participant responses between 2000 and 2007 were evaluated for esophageal wash/brush, gastric wash/brush, and biliary tract brush specimens with a reference diagnosis of adenocarcinoma, squamous cell carcinoma, carcinoid, or spindle cell neoplasm.

Overall performance of cytotechnologists was not different from that of pathologists (89.2% versus 89.0%; P = .75).

Cytotechnologists had better performance for detecting squamous cell carcinoma (96.3% versus 92.6%; P < .001), while pathologists had better performance for detecting spindle cell neoplasm (79.7% versus 42.9%; P < .001).

Cytotechnologists and pathologists performed at the same level overall, but with differences for the diagnosis of spindle cell neoplasm and squamous carcinoma.

[MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Gastrointestinal Neoplasms / diagnosis. Laboratories, Hospital / standards. Pathology, Clinical / methods

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20670130.001).

[ISSN] 1543-2165

[Journal-full-title] Archives of pathology & laboratory medicine

[ISO-abbreviation] Arch. Pathol. Lab. Med.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

There were 9 patients with Stage III disease and 7 with Stage IV disease.

All tumors were squamous cell carcinomas.

[MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Fistula / drug therapy. Esophageal Fistula / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy

Genetic Alliance. consumer health - Esophageal Cancer.

MedlinePlus Health Information. consumer health - Esophageal Cancer.

Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

Hazardous Substances Data Bank. FLUOROURACIL .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18234437.001).

[ISSN] 0360-3016

[Journal-full-title] International journal of radiation oncology, biology, physics

[ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

While chemotherapy provides useful palliation, advanced lung cancer remains incurable since those tumors that are initially sensitive to therapy rapidly develop acquired resistance.

Resistance may arise from impaired drug delivery, extracellular factors, decreased drug uptake into tumor cells, increased drug efflux, drug inactivation by detoxifying factors, decreased drug activation or binding to target, altered target, increased damage repair, tolerance of damage, decreased proapoptotic factors, increased antiapoptotic factors, or altered cell cycling or transcription factors.

Factors for which there is now substantial clinical evidence of a link to small cell lung cancer (SCLC) resistance to chemotherapy include MRP (for platinum-based combination chemotherapy) and MDR1/P-gp (for non-platinum agents).

In non-small cell lung cancer (NSCLC), the strongest clinical evidence is for taxane resistance with elevated expression or mutation of class III beta-tubulin (and possibly alpha tubulin), platinum resistance and expression of ERCC1 or BCRP, gemcitabine resistance and RRM1 expression, and resistance to several agents and COX-2 expression (although COX-2 inhibitors have had minimal impact on drug efficacy clinically).

Tumors expressing high BRCA1 may have increased resistance to platinums but increased sensitivity to taxanes.

Limited early clinical data suggest that chemotherapy resistance in NSCLC may also be increased with decreased expression of cyclin B1 or of Eg5, or with increased expression of ICAM, matrilysin, osteopontin, DDH, survivin, PCDGF, caveolin-1, p21WAF1/CIP1, or 14-3-3sigma, and that IGF-1R inhibitors may increase efficacy of chemotherapy, particularly in squamous cell carcinomas.

Equivocal data (with some positive studies but other negative studies) suggest that NSCLC tumors with some EGFR mutations may have increased sensitivity to chemotherapy, while K-ras mutations and expression of GST-pi, RB or p27kip1 may possibly confer resistance.

To date, resistance-modulating strategies have generally not proven clinically useful in lung cancer, although small randomized trials suggest a modest benefit of verapamil and related agents in NSCLC.

Genetic Alliance. consumer health - Lung Cancer.

Genetic Alliance. consumer health - Non-small cell lung cancer.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - Lung Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Published by Elsevier Ireland Ltd.

[Cites] Oncol Res. 1996;8(6):229-38 [8895198.001]

[Cites] Invest New Drugs. 1996;14(2):115-30 [8913832.001]

[Cites] Cell Growth Differ. 1996 Nov;7(11):1507-12 [8930400.001]

[Cites] J Clin Oncol. 1997 Jan;15(1):285-91 [8996154.001]

[Cites] Cancer Chemother Pharmacol. 1997;39(3):192-8 [8996519.001]

[Cites] Eur J Cancer. 1996 Nov;32A(12):2136-41 [9014757.001]

[Cites] Med Oncol. 1998 Dec;15(4):255-61 [9951689.001]

[Cites] Clin Nucl Med. 1999 Feb;24(2):97-101 [9988065.001]

[Cites] Korean J Intern Med. 1999 Jan;14(1):42-52 [10063313.001]

[Cites] Jpn J Cancer Res. 1999 Jan;90(1):108-15 [10076573.001]

[Cites] J Thorac Cardiovasc Surg. 1999 Apr;117(4):744-50 [10096970.001]

[Cites] Cell Death Differ. 1999 Feb;6(2):130-5 [10200559.001]

[Cites] Anticancer Res. 1999 Jan-Feb;19(1A):221-8 [10226546.001]

[Cites] Br J Cancer. 1999 Jun;80(7):1020-5 [10362110.001]

[Cites] Zhongguo Yao Li Xue Bao. 1998 May;19(3):265-8 [10375741.001]

[Cites] J Cancer Res Clin Oncol. 1999 Jul;125(7):389-94 [10394958.001]

[Cites] Int J Cancer. 1999 Jul 30;82(3):368-76 [10399954.001]

[Cites] Cancer Chemother Pharmacol. 1999;44(3):193-202 [10453720.001]

[Cites] Clin Cancer Res. 1999 Aug;5(8):2048-58 [10473085.001]

[Cites] Anticancer Res. 1999 May-Jun;19(3B):2311-5 [10472350.001]

[Cites] Br J Cancer. 2005 Jan 17;92(1):131-9 [15597105.001]

[Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805 [15701870.001]

[Cites] Cancer Res. 2005 Feb 1;65(3):991-8 [15705900.001]

[Cites] Cancer Res. 1999 Sep 15;59(18):4529-34 [10493501.001]

[Cites] Int J Oncol. 1999 Oct;15(4):693-9 [10493950.001]

[Cites] J Appl Physiol. 1963 Jan;18:197-204 [13932730.001]

[Cites] Br J Cancer. 1993 Oct;68(4):813-8 [8398713.001]

[Cites] Anticancer Drugs. 1993 Aug;4(4):491-500 [8400352.001]

[Cites] Cancer Res. 1993 Oct 15;53(20):4866-73 [8104687.001]

[Cites] Acta Med Okayama. 1993 Aug;47(4):243-8 [8213218.001]

[Cites] J Thorac Cardiovasc Surg. 1994 Jan;107(1):43-9 [8283917.001]

[Cites] Cancer Lett. 1993 Dec 10;75(2):111-9 [8293421.001]

[Cites] Cancer. 1994 Mar 1;73(5):1377-82 [8111704.001]

[Cites] Cancer Res. 1994 May 1;54(9):2287-91 [8162565.001]

[Cites] Jpn J Cancer Res. 1994 Mar;85(3):290-7 [7514586.001]

[Cites] Cancer Chemother Pharmacol. 1994;34(3):242-8 [8004758.001]

[Cites] Am J Clin Oncol. 1994 Aug;17(4):313-6 [8048393.001]

[Cites] Br J Cancer. 1994 Aug;70(2):190-4 [7914420.001]

[Cites] Oncogene. 1994 Sep;9(9):2441-8 [8058306.001]

[Cites] Gan To Kagaku Ryoho. 1994 Dec;21(16):2749-55 [7993110.001]

[Cites] Br J Cancer. 1995 Jan;71(1):40-7 [7819046.001]

[Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2727-30 [7872708.001]

[Cites] Am J Clin Oncol. 1995 Jun;18(3):185-8 [7747703.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7690-4 [7644478.001]

[Cites] Br J Cancer. 1995 Sep;72(3):550-4 [7669560.001]

[Cites] Respiration. 1995;62(4):223-7 [8578019.001]

[Cites] Cancer Res. 1995 Nov 1;55(21):5038-42 [7585548.001]

[Cites] Biochem Biophys Res Commun. 1995 Nov 2;216(1):258-64 [7488097.001]

[Cites] Int J Cancer. 1995 Nov 27;63(5):688-93 [7591286.001]

[Cites] Cancer Res. 1996 Jan 1;56(1):206-9 [8548764.001]

[Cites] Eur J Cancer. 1995 Oct;31A(11):1862-8 [8541114.001]

[Cites] Jpn J Clin Oncol. 1996 Feb;26(1):1-5 [8551660.001]

[Cites] Semin Oncol. 1995 Dec;22(6 Suppl 14):12-8 [8553077.001]

[Cites] Cancer Res. 1996 Mar 15;56(6):1232-6 [8640804.001]

[Cites] Cancer. 1996 May 1;77(9):1797-808 [8646677.001]

[Cites] Cancer Res. 1996 Feb 15;56(4):794-801 [8631016.001]

[Cites] Clin Cancer Res. 2005 Sep 15;11(18):6634-40 [16166442.001]

[Cites] Cancer Res. 2005 Oct 1;65(19):8613-6 [16204026.001]

[Cites] Lung Cancer. 2005 Nov;50(2):211-9 [16169122.001]

[Cites] Cancer Res. 2005 Oct 15;65(20):9169-75 [16230375.001]

[Cites] Int J Cancer. 2005 Dec 10;117(5):755-63 [15981204.001]

[Cites] Cancer Biol Ther. 2005 Mar;4(3):267-76 [15753661.001]

[Cites] Cancer Chemother Pharmacol. 2005 Nov;56(5):473-80 [15895231.001]

[Cites] Cancer Sci. 2005 Nov;96(11):774-83 [16271071.001]

[Cites] Int J Cancer. 2006 Jan 15;118(2):317-25 [16080190.001]

[Cites] Anticancer Res. 2005 Nov-Dec;25(6B):3865-70 [16309172.001]

[Cites] Eur J Cancer. 1999 Jun;35(6):1020-6 [10533488.001]

[Cites] Cancer. 1999 Oct 15;86(8):1470-9 [10526275.001]

[Cites] J Nucl Med. 1999 Nov;40(11):1778-83 [10565770.001]

[Cites] Br J Cancer. 1997;75(6):869-77 [9062409.001]

[Cites] Anticancer Res. 1997 Jan-Feb;17(1B):721-4 [9066608.001]

[Cites] Tohoku J Exp Med. 1997 Mar;181(3):361-70 [9163851.001]

[Cites] Am J Clin Oncol. 1997 Aug;20(4):398-403 [9256898.001]

[Cites] Lung Cancer. 1997 Oct;18(2):189-98 [9316010.001]

[Cites] Cancer Res. 1997 Oct 15;57(20):4451-4 [9377550.001]

[Cites] Int J Cancer. 1997 Nov 14;73(4):544-50 [9389570.001]

[Cites] Anticancer Res. 1997 Sep-Oct;17(5A):3345-8 [9413170.001]

[Cites] Anticancer Res. 1997 Sep-Oct;17(5A):3493-7 [9413193.001]

[Cites] Nucl Med Commun. 1997 Nov;18(11):1087-97 [9423210.001]

[Cites] Anticancer Res. 1997 Sep-Oct;17(5B):3777-80 [9427779.001]

[Cites] J Cell Biochem Suppl. 1996;24:173-85 [8806100.001]

[Cites] Cancer. 1996 Sep 15;78(6):1203-10 [8826941.001]

[Cites] Lung Cancer. 1996 Aug;15(1):115-23 [8865129.001]

[Cites] Ann Oncol. 1996 Aug;7(6):625-30 [8879378.001]

[Cites] Br J Cancer. 2000 Feb;82(4):924-30 [10732767.001]

[Cites] Eur J Cancer. 2000 Mar;36(4):489-95 [10717525.001]

[Cites] Int J Cancer. 2000 Mar 20;89(2):160-6 [10754494.001]

[Cites] Cancer Chemother Pharmacol. 1997;41(1):1-8 [9443607.001]

[Cites] J Nucl Med. 1998 Jan;39(1):91-4 [9443743.001]

[Cites] Oncol Rep. 1998 Jan-Feb;5(1):249-55 [9458331.001]

[Cites] Br J Cancer. 1998 Feb;77(4):627-31 [9484821.001]

[Cites] Invest New Drugs. 1997;15(4):267-77 [9547669.001]

[Cites] Br J Cancer. 1998 Apr;77(8):1363-8 [9579847.001]

[Cites] J Surg Oncol. 1998 May;68(1):19-24 [9610658.001]

[Cites] Anticancer Res. 1998 Mar-Apr;18(2A):927-33 [9615743.001]

[Cites] Anticancer Res. 1998 Mar-Apr;18(2A):1079-84 [9615769.001]

[Cites] Anticancer Res. 1998 Mar-Apr;18(2A):1085-9 [9615770.001]

[Cites] Br J Cancer. 1998 May;77(9):1469-73 [9652763.001]

[Cites] J Cancer Res Clin Oncol. 1998;124(2):106-12 [9654193.001]

[Cites] Int J Oncol. 1998 Sep;13(3):543-8 [9683791.001]

[Cites] Anticancer Res. 1998 Jul-Aug;18(4C):2957-60 [9713491.001]

[Cites] Anticancer Res. 1998 Jul-Aug;18(4C):3077-80 [9713513.001]

[Cites] J Nucl Med. 1998 Sep;39(9):1626-9 [9744357.001]

[Cites] Cancer Lett. 1998 Aug 14;130(1-2):133-41 [9751266.001]

[Cites] Oncogene. 1998 Oct 15;17(15):1923-30 [9788435.001]

[Cites] Br J Cancer. 1998 Oct;78(8):1035-42 [9792147.001]

[Cites] Gene. 1998 Nov 5;222(1):61-7 [9813242.001]

[Cites] Clin Cancer Res. 1996 Feb;2(2):359-67 [9816179.001]

[Cites] Clin Cancer Res. 1997 Jan;3(1):115-22 [9815546.001]

[Cites] Mod Pathol. 1998 Nov;11(11):1059-63 [9831202.001]

[Cites] FEBS Lett. 1998 Nov 20;439(3):368-72 [9845355.001]

[Cites] Eur J Cancer. 1998 Aug;34(9):1352-7 [9849416.001]

[Cites] Eur J Cancer. 1998 Jul;34(8):1250-9 [9849488.001]

[Cites] Lung Cancer. 1998 Sep;21(3):203-11 [9857998.001]

[Cites] Oncogene. 1998 Dec 17;17(24):3177-86 [9872333.001]

[Cites] Anticancer Res. 1998 Nov-Dec;18(6A):4159-62 [9891461.001]

[Cites] Eur J Cancer. 1998 Oct;34(11):1749-55 [9893664.001]

[Cites] Mol Pathol. 1998 Aug;51(4):191-200 [9893744.001]

[Cites] Clin Cancer Res. 1997 May;3(5):741-7 [9815744.001]

[Cites] Clin Cancer Res. 1997 Jul;3(7):1195-200 [9815799.001]

[Cites] Oncol Res. 1995;7(7-8):371-9 [8747600.001]

[Cites] Anticancer Res. 1996 Jul-Aug;16(4A):1603-10 [8712677.001]

[Cites] Anticancer Res. 1996 Jul-Aug;16(4A):1963-70 [8712728.001]

[Cites] Cancer. 1996 Aug 1;78(3):416-21 [8697385.001]

[Cites] Cancer. 1996 Aug 15;78(4):729-35 [8756364.001]

[Cites] J Cancer Res Clin Oncol. 1995;121 Suppl 3:R17-20 [8698737.001]

[Cites] Oncology. 1996 Sep-Oct;53(5):417-21 [8784478.001]

[Cites] Cancer Res. 2007 Jul 1;67(13):6325-32 [17616691.001]

[Cites] Oncogene. 2007 Jul 19;26(33):4749-60 [17297441.001]

[Cites] Zhonghua Yi Xue Za Zhi. 2007 Apr 3;87(13):924-6 [17650408.001]

[Cites] Braz J Med Biol Res. 2007 Aug;40(8):1149-57 [17665053.001]

[Cites] Oncologist. 2007 Jul;12(7):808-15 [17673612.001]

[Cites] Autophagy. 2007 Sep-Oct;3(5):464-7 [17495516.001]

[Cites] Cancer Sci. 2007 Sep;98(9):1394-401 [17608771.001]

[Cites] Cancer Sci. 2007 Sep;98(9):1336-43 [17640298.001]

[Cites] Anticancer Res. 2007 Jul-Aug;27(4B):2359-64 [17695526.001]

[Cites] Cancer Res. 2007 Aug 15;67(16):7901-6 [17699796.001]

[Cites] J Thorac Oncol. 2007 Aug;2(8):745-50 [17762342.001]

[Cites] Cancer Lett. 2007 Oct 18;256(1):112-9 [17658213.001]

[Cites] Cancer Res. 2007 Sep 1;67(17):7954-9 [17804701.001]

[Cites] Chin Med J (Engl). 2004 Nov;117(11):1642-9 [15569479.001]

[Cites] Clin Cancer Res. 2004 Nov 15;10(22):7662-70 [15569999.001]

[Cites] Clin Cancer Res. 2004 Dec 1;10(23):7986-93 [15585634.001]

[Cites] Mol Cancer Ther. 2004 Dec;3(12):1543-9 [15634647.001]

[Cites] Oncol Rep. 2005 Feb;13(2):217-22 [15643501.001]

[Cites] Oncol Rep. 2005 Feb;13(2):259-64 [15643508.001]

[Cites] Clin Lung Cancer. 2005 Jan;6(4):250-4 [15694018.001]

[Cites] Exp Lung Res. 2004 Dec;30(8):687-703 [15700547.001]

[Cites] Br J Cancer. 2007 Oct 22;97(8):1077-83 [17940500.001]

[Cites] Int J Oncol. 2007 Dec;31(6):1325-32 [17982658.001]

[Cites] Oncol Rep. 2007 Dec;18(6):1499-505 [17982636.001]

[Cites] Anticancer Res. 2004 Nov-Dec;24(6):3911-6 [15736431.001]

[Cites] Clin Cancer Res. 2005 Feb 15;11(4):1563-71 [15746061.001]

[Cites] Bull Cancer. 2005 Feb;92(2):E25-30 [15749640.001]

[Cites] Lung Cancer. 2005 Apr;48(1):59-67 [15777971.001]

[Cites] Cancer Invest. 2005;23(1):26-32 [15779865.001]

[Cites] Br J Cancer. 2005 Mar 28;92(6):1084-8 [15756274.001]

[Cites] Biol Pharm Bull. 2005 Apr;28(4):707-12 [15802814.001]

[Cites] Cancer Res. 2005 Apr 1;65(7):2795-803 [15805280.001]

[Cites] Ai Zheng. 2005 Apr;24(4):403-7 [15820060.001]

[Cites] Lung Cancer. 2005 May;48(2):267-73 [15829328.001]

[Cites] Cancer Biol Ther. 2004 Oct;3(10):954-9 [15326378.001]

[Cites] Clin Lung Cancer. 2005 Mar;6(5):299-303 [15845181.001]

[Cites] Zhonghua Jie He He Hu Xi Za Zhi. 2005 Feb;28(2):102-7 [15854392.001]

[Cites] Cancer Biol Ther. 2004 Dec;3(12):1262-9 [15611646.001]

[Cites] Anticancer Res. 2005 Mar-Apr;25(2B):1427-31 [15865101.001]

[Cites] Cancer Res. 2005 May 1;65(9):3883-93 [15867388.001]

[Cites] Oncol Rep. 2005 Jun;13(6):1229-34 [15870947.001]

[Cites] Langenbecks Arch Surg. 2005 Jun;390(3):243-8 [15726400.001]

[Cites] Cancer Chemother Pharmacol. 2005 Aug;56(2):212-20 [15812674.001]

[Cites] Cancer Res. 2005 Jun 15;65(12):4998-5002 [15958539.001]

[Cites] Mol Pharmacol. 2005 Jul;68(1):110-8 [15795320.001]

[Cites] Oncogene. 2005 Jun 23;24(27):4462-71 [15806155.001]

[Cites] Biochem Pharmacol. 2005 Aug 1;70(3):481-8 [15950949.001]

[Cites] In Vivo. 2005 Jul-Aug;19(4):717-21 [15999539.001]

[Cites] Oncol Rep. 2005 Aug;14(2):421-4 [16012725.001]

[Cites] Ann Thorac Cardiovasc Surg. 2005 Jun;11(3):143-5 [16030471.001]

[Cites] Cancer. 2005 Aug 1;104(3):561-9 [16028213.001]

[Cites] Cancer J. 2005 May-Jun;11(3):209-16 [16053664.001]

[Cites] Mol Cancer. 2005;4(1):25 [16033649.001]

[Cites] Cancer Res. 2005 Aug 1;65(15):6934-42 [16061678.001]

[Cites] Cancer Res. 2005 Aug 1;65(15):6943-9 [16061679.001]

[Cites] Clin Cancer Res. 2005 Aug 1;11(15):5481-6 [16061864.001]

[Cites] Lung. 2005 May-Jun;183(3):177-83 [16078039.001]

[Cites] Oncogene. 1996 Feb 1;12(3):571-6 [8637714.001]

[Cites] Cancer Res. 1996 Mar 1;56(5):1068-74 [8640763.001]

[Cites] Int J Cancer. 1996 Jun 11;66(6):760-7 [8647646.001]

[Cites] J Clin Oncol. 2005 Sep 1;23(25):5900-9 [16043828.001]

[Cites] J Clin Oncol. 2005 Sep 1;23(25):5892-9 [16043829.001]

[Cites] Anticancer Drugs. 2005 Oct;16(9):969-76 [16162973.001]

[Cites] Cancer Res. 2005 Sep 15;65(18):8423-32 [16166321.001]

[Cites] Respiration. 2008;75(4):380-5 [17851225.001]

[Cites] Oncogene. 2008 May 15;27(22):3134-44 [18071312.001]

[Cites] Clin Cancer Res. 2008 May 15;14(10):3083-8 [18483375.001]

[Cites] Mol Cancer Ther. 2008 May;7(5):1150-5 [18445659.001]

[Cites] Respirology. 2008 Jun;13(4):510-7 [18494946.001]

[Cites] Nan Fang Yi Ke Da Xue Xue Bao. 2008 May;28(5):770-3 [18504201.001]

[Cites] Anticancer Res. 2008 Mar-Apr;28(2A):601-8 [18506998.001]

[Cites] Lung Cancer. 2008 Jun;60(3):416-25 [18077053.001]

[Cites] J Thorac Oncol. 2008 Jun;3(6):583-9 [18520795.001]

[Cites] Acta Biochim Biophys Sin (Shanghai). 2008 Jun;40(6):497-504 [18535748.001]

[Cites] J Clin Oncol. 2008 Jun 10;26(17):2839-45 [18539962.001]

[Cites] J Clin Oncol. 2008 Jun 10;26(17):2883-9 [18539968.001]

[Cites] Ai Zheng. 2008 Jun;27(6):575-9 [18570728.001]

[Cites] Oncology. 1999 Nov;57(4):318-23 [10575319.001]

[Cites] Int J Cancer. 1999 Dec 10;83(6):790-7 [10597196.001]

[Cites] Lung Cancer. 1999 Dec;26(3):187-94 [10598929.001]

[Cites] Oncol Rep. 2000 Jan-Feb;7(1):49-52 [10601590.001]

[Cites] Cancer Res. 1999 Dec 15;59(24):6178-84 [10626810.001]

[Cites] J Biomed Sci. 2000 Jan-Feb;7(1):64-70 [10644891.001]

[Cites] FEBS Lett. 2000 Jan 14;465(2-3):124-8 [10631318.001]

[Cites] Int J Cancer. 2000 Apr 1;86(1):95-100 [10728601.001]

[Cites] Carcinogenesis. 2008 Jul;29(7):1448-58 [18544565.001]

[Cites] Mol Pharmacol. 2008 Sep;74(3):854-62 [18524888.001]

[Cites] Cell Biol Int. 2008 Sep;32(9):1031-43 [18550395.001]

[Cites] Jpn J Cancer Res. 2000 Feb;91(2):213-22 [10761709.001]

[Cites] Exp Mol Med. 2000 Mar 31;32(1):23-8 [10762058.001]

[Cites] Kidney Int. 2000 Apr;57(4):1617-35 [10760097.001]

[Cites] Cancer Gene Ther. 2000 Feb;7(2):300-7 [10770640.001]

[Cites] Oncol Rep. 2000 May-Jun;7(3):491-5 [10767357.001]

[Cites] Clin Nucl Med. 2000 May;25(5):364-9 [10795697.001]

[Cites] Biochem Pharmacol. 1999 May 1;57(9):1047-58 [10796075.001]

[Cites] Anticancer Res. 2000 Mar-Apr;20(2A):693-702 [10810342.001]

[Cites] Clin Cancer Res. 2000 May;6(5):2006-11 [10815926.001]

[Cites] Cancer Res. 2000 Jun 1;60(11):2805-9 [10850418.001]

[Cites] Br J Cancer. 2000 Jul;83(1):83-8 [10883672.001]

[Cites] Cancer Lett. 2000 Aug 31;157(1):105-12 [10893449.001]

[Cites] Clin Cancer Res. 2000 Jul;6(7):2860-7 [10914735.001]

[Cites] Eur J Cancer. 2000 Aug;36(12):1565-71 [10930805.001]

[Cites] Cancer Detect Prev. 2000;24(3):252-7 [10975287.001]

[Cites] Int J Cancer. 2000 Oct 15;88(2):293-300 [11004683.001]

[Cites] Ann Thorac Surg. 2000 Sep;70(3):930-6; discussion 936-7 [11016336.001]

[Cites] Oncol Rep. 2000 Nov-Dec;7(6):1225-8 [11032919.001]

[Cites] Ann Oncol. 2000 Nov;11(11):1395-7 [11142478.001]

[Cites] Cell. 2007 May 4;129(3):465-72 [17482542.001]

[Cites] Acta Biochim Biophys Sin (Shanghai). 2007 May;39(5):344-50 [17492131.001]

[Cites] Clin Cancer Res. 2007 May 15;13(10):2876-81 [17504986.001]

[Cites] Cancer Res. 2007 May 15;67(10):4827-33 [17510412.001]

[Cites] Cancer. 2007 May 1;109(9):1829-35 [17366594.001]

[Cites] Cancer Lett. 2007 Jul 18;252(2):225-34 [17276588.001]

[Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):12-31 [17336087.001]

[Cites] Lancet Oncol. 2007 Jun;8(6):500-12 [17513173.001]

[Cites] Clin Cancer Res. 2007 Jun 1;13(11):3413-22 [17545550.001]

[Cites] Cancer Chemother Pharmacol. 2007 Aug;60(3):449-57 [17569045.001]

[Cites] Anticancer Drugs. 2007 Aug;18(7):755-61 [17581297.001]

[Cites] Cancer. 2007 Jul 1;110(1):138-47 [17534875.001]

[Cites] Cells Tissues Organs. 2007;185(1-3):162-74 [17587822.001]

[Cites] Anticancer Res. 2007 May-Jun;27(3A):1361-4 [17593631.001]

[Cites] Cancer Chemother Pharmacol. 1999;43(1):29-34 [9923538.001]

[Cites] Cancer Biochem Biophys. 1998 Nov;16(4):347-63 [9925282.001]

[Cites] Oncogene. 1999 Jan 14;18(2):477-85 [9927204.001]

[Cites] J Clin Oncol. 2007 Jul 1;25(19):2741-6 [17602079.001]

[Cites] J Clin Oncol. 2007 Jul 1;25(19):2747-54 [17602080.001]

[Cites] Clin Cancer Res. 2007 Jul 1;13(13):3892-8 [17606722.001]

[Cites] Int J Oncol. 2007 Aug;31(2):461-6 [17611704.001]

[Cites] Cancer Res. 2009 Apr 15;69(8):3390-6 [19351853.001]

[Cites] Mol Cancer Ther. 2009 Apr;8(4):980-7 [19372571.001]

[Cites] Int J Cancer. 2009 Jun 15;124(12):2997-3001 [19267403.001]

[Cites] Cancer Lett. 2009 Jun 28;279(1):57-64 [19217709.001]

[Cites] Anticancer Res. 2009 Apr;29(4):1157-62 [19414359.001]

[Cites] Biomaterials. 2009 Jul;30(20):3476-85 [19345990.001]

[Cites] Curr Cancer Drug Targets. 2009 May;9(3):354-65 [19442054.001]

[Cites] J Clin Oncol. 2009 May 20;27(15):2516-22 [19380445.001]

[Cites] Clin Cancer Res. 2009 Jun 1;15(11):3881-8 [19470736.001]

[Cites] Oncogene. 2009 May 28;28(21):2163-72 [19377513.001]

[Cites] Lung Cancer. 2009 Aug;65(2):230-6 [19157633.001]

[Cites] Clin Cancer Res. 2009 Jul 1;15(13):4312-21 [19509135.001]

[Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]

[Cites] Cancer Res. 2007 Sep 1;67(17):8051-7 [17804716.001]

[Cites] J Surg Res. 2007 Oct;142(2):364-72 [17640669.001]

[Cites] J Clin Oncol. 2007 Oct 1;25(28):4350-7 [17906199.001]

[Cites] Cancer Res. 2007 Oct 1;67(19):9356-63 [17909044.001]

[Cites] Int J Cancer. 2007 Dec 1;121(11):2387-94 [17688235.001]

[Cites] J Thorac Oncol. 2007 Oct;2(10):902-6 [17909351.001]

[Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]

[Cites] J BUON. 2007 Sep;12 Suppl 1:S67-70 [17935280.001]

[Cites] Lung Cancer. 2010 Jan;67(1):31-6 [19375813.001]

[Cites] J Thorac Oncol. 2009 Dec;4(12):1537-43 [19887966.001]

[Cites] Oncol Rep. 2006 Jan;15(1):283-6 [16328069.001]

[Cites] PLoS One. 2007;2(11):e1129 [17987116.001]

[Cites] Acta Biochim Biophys Sin (Shanghai). 2007 Nov;39(11):835-43 [17989874.001]

[Cites] J Clin Oncol. 2007 Nov 20;25(33):5240-7 [18024870.001]

[Cites] Biochem Biophys Res Commun. 2008 Jan 4;365(1):35-41 [17980703.001]

[Cites] Cancer Detect Prev. 2007;31(5):366-70 [18035504.001]

[Cites] Nucleosides Nucleotides Nucleic Acids. 2007;26(10-12):1577-9 [18066830.001]

[Cites] Cancer Gene Ther. 2008 Jan;15(1):29-39 [17828283.001]

[Cites] J Pathol. 2008 Jan;214(1):3-9 [18067118.001]

[Cites] Cancer Chemother Pharmacol. 2008 Mar;61(3):525-34 [17505826.001]

[Cites] Mol Pharmacol. 2008 Jan;73(1):119-27 [17911532.001]

[Cites] IUBMB Life. 2007 Nov;59(11):696-9 [17885832.001]

[Cites] Oncol Rep. 2008 Jan;19(1):203-9 [18097596.001]

[Cites] Lung Cancer. 2008 Jan;59(1):69-75 [17766002.001]

[Cites] Lung Cancer. 2008 Jan;59(1):105-10 [17850918.001]

[Cites] Lung Cancer. 2008 Jan;59(1):95-104 [17889401.001]

[Cites] Clin Lung Cancer. 2007 Nov;8(9):548-53 [18186959.001]

[Cites] Cancer Res. 2008 Jan 15;68(2):589-96 [18199556.001]

[Cites] Anticancer Res. 2007 Nov-Dec;27(6C):4351-8 [18214043.001]

[Cites] J Clin Oncol. 2008 Feb 1;26(4):639-43 [18235124.001]

[Cites] J Clin Oncol. 2008 Feb 20;26(6):848-55 [18281656.001]

[Cites] J Clin Oncol. 2008 Feb 20;26(6):870-6 [18281659.001]

[Cites] Int J Radiat Biol. 2007 Nov-Dec;83(11-12):733-41 [17852559.001]

[Cites] Int J Cancer. 2008 Apr 15;122(8):1810-9 [18074354.001]

[Cites] Cancer Res. 2008 Mar 1;68(5):1303-9 [18316592.001]

[Cites] Clin Cancer Res. 2008 Mar 1;14(5):1407-12 [18316562.001]

[Cites] Lung Cancer. 2008 Mar;59(3):377-84 [17905465.001]

[Cites] Clin Cancer Res. 2008 Mar 15;14(6):1797-803 [18347182.001]

[Cites] Mol Pharmacol. 2008 Apr;73(4):1290-300 [18187583.001]

[Cites] Neoplasma. 2008;55(3):200-4 [18348652.001]

[Cites] Int J Cancer. 2008 May 15;122(10):2380-4 [18224693.001]

[Cites] Lung Cancer. 2008 Apr;60(1):47-56 [18006113.001]

[Cites] Biochem Biophys Res Commun. 2008 May 16;369(4):1098-102 [18331824.001]

[Cites] Mol Cancer Ther. 2008 Apr;7(4):980-92 [18413811.001]

[Cites] Cancer Biol Ther. 2005 May;4(5):538-45 [15846106.001]

[Cites] Lung Cancer. 2005 Sep;49(3):363-70 [15923058.001]

[Cites] Lung Cancer. 2005 Sep;49(3):337-43 [15955594.001]

[Cites] Arch Pharm Res. 2008 Apr;31(4):539-46 [18449514.001]

[Cites] Cancer Res. 2008 May 1;68(9):3243-50 [18451150.001]

[Cites] J Thorac Cardiovasc Surg. 2008 May;135(5):1036-41 [18455581.001]

[Cites] Br J Cancer. 2008 May 20;98(10):1710-5 [18414411.001]

[Cites] Anticancer Res. 2006 Jul-Aug;26(4B):2949-55 [16886619.001]

[Cites] Mol Cancer Ther. 2006 Jul;5(7):1800-6 [16891466.001]

[Cites] BMC Cancer. 2006;6:174 [16813650.001]

[Cites] BMC Cancer. 2006;6:166 [16796750.001]

[Cites] Nat Rev Mol Cell Biol. 2006 Sep;7(9):678-89 [16921404.001]

[Cites] Exp Cell Res. 2006 Sep 10;312(15):2806-15 [16781710.001]

[Cites] Bull Cancer. 2006 Aug;93(8):E101-8 [16935774.001]

[Cites] Br J Cancer. 2006 Sep 4;95(5):601-6 [16909136.001]

[Cites] Cancer Res. 2006 Sep 1;66(17):8731-9 [16951189.001]

[Cites] Cancer Res. 2006 Sep 1;66(17):8870-7 [16951204.001]

[Cites] Cancer Chemother Pharmacol. 2006 Dec;58(6):776-84 [16532342.001]

[Cites] N Engl J Med. 2006 Sep 7;355(10):983-91 [16957145.001]

[Cites] Cell Death Differ. 2006 Oct;13(10):1776-88 [16410797.001]

[Cites] J Biol Chem. 2008 Jun 27;283(26):18218-26 [18458078.001]

[Cites] Carcinogenesis. 2008 Jun;29(6):1235-43 [18413364.001]

[Cites] PLoS One. 2008;3(7):e2637 [18612434.001]

[Cites] Oncol Rep. 2008 Aug;20(2):265-70 [18636185.001]

[Cites] J Clin Oncol. 2008 Jul 20;26(21):3543-51 [18506025.001]

[Cites] J Int Med Res. 2008 Jul-Aug;36(4):734-47 [18652770.001]

[Cites] Cancer Genet Cytogenet. 2008 Aug;185(1):11-9 [18656688.001]

[Cites] Cancer. 2008 Aug 15;113(4):799-807 [18618574.001]

[Cites] Clin Cancer Res. 2006 Oct 1;12(19):5720-5 [17020976.001]

[Cites] Cancer Lett. 2006 Oct 28;242(2):231-8 [16427189.001]

[Cites] Cancer Lett. 2006 Nov 28;244(1):53-60 [16446029.001]

[Cites] Oncogene. 2008 Sep 1;27(38):5124-31 [18758481.001]

[Cites] Cancer Biol Ther. 2008 Aug;7(8):1250-61 [18487950.001]

[Cites] Cancer. 2008 Sep 15;113(6):1379-86 [18623378.001]

[Cites] J Thorac Oncol. 2008 Oct;3(10):1112-8 [18827606.001]

[Cites] Cancer Res. 2008 Oct 1;68(19):7975-84 [18829555.001]

[Cites] Clin Cancer Res. 2008 Oct 1;14(19):6317-23 [18829515.001]

[Cites] J Clin Oncol. 2008 Oct 10;26(29):4849-50; author reply 4850-1 [18779595.001]

[Cites] J Clin Oncol. 2008 Oct 10;26(29):4771-6 [18779603.001]

[Cites] Mol Cancer Ther. 2008 Oct;7(10):3141-9 [18852117.001]

[Cites] Anticancer Agents Med Chem. 2008 Oct;8(7):790-7 [18855580.001]

[Cites] Pharmacogenet Genomics. 2008 Nov;18(11):955-65 [18854777.001]

[Cites] Lung Cancer. 2008 Oct;62(1):8-14 [18372076.001]

[Cites] J Thorac Oncol. 2008 Nov;3(11):1293-300 [18978565.001]

[Cites] PLoS One. 2008;3(11):e3695 [19002265.001]

[Cites] Anticancer Res. 2008 Sep-Oct;28(5B):2967-74 [19031941.001]

[Cites] Cancer Sci. 2008 Nov;99(11):2185-92 [18823373.001]

[Cites] J Biol Inorg Chem. 2009 Jan;14(1):123-32 [18797938.001]

[Cites] Lung Cancer. 2008 Dec;62(3):356-63 [18501466.001]

[Cites] J Thorac Oncol. 2008 Dec;3(12):1454-9 [19057272.001]

[Cites] Onkologie. 2008 Dec;31(12):665-70 [19060504.001]

[Cites] Clin Transl Oncol. 2008 Dec;10(12):786-93 [19068449.001]

[Cites] Oncol Rep. 2009 Jan;21(1):263-8 [19082471.001]

[Cites] J Clin Oncol. 2008 Dec 20;26(36):5972-9 [19018088.001]

[Cites] Cancer. 2008 Dec 25;114(6):519-26 [19006072.001]

[Cites] Cell Mol Life Sci. 2009 Jan;66(1):43-61 [18759128.001]

[Cites] Am J Respir Cell Mol Biol. 2009 Feb;40(2):135-46 [18676776.001]

[Cites] J Clin Oncol. 2009 Jan 20;27(3):328-33 [19064964.001]

[Cites] Zhonghua Yi Xue Za Zhi. 2008 Nov 25;88(43):3059-62 [19192406.001]

[Cites] Int J Oncol. 2009 Mar;34(3):689-96 [19212674.001]

[Cites] Lung Cancer. 2009 Apr;64(1):98-104 [18823676.001]

[Cites] Vojnosanit Pregl. 2009 Feb;66(2):149-55 [19281127.001]

[Cites] Clin Cancer Res. 2009 Mar 15;15(6):2158-65 [19276291.001]

[Cites] Mol Cancer Res. 2009 Mar;7(3):393-401 [19240180.001]

[Cites] Int J Cancer. 2007 Aug 15;121(4):895-900 [17417781.001]

[Cites] J Cell Physiol. 2007 Sep;212(3):710-6 [17458894.001]

[Cites] J Clin Oncol. 2007 Jul 1;25(19):2735-40 [17602078.001]

[Cites] J Thorac Oncol. 2009 Apr;4(4):486-91 [19240654.001]

[Cites] Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5312-7 [19279207.001]

[Cites] J Thorac Oncol. 2009 Apr;4(4):479-85 [19347979.001]

[Cites] Cancer Invest. 2009 May;27(4):391-6 [19266367.001]

[Cites] Clin Cancer Res. 2000 Dec;6(12):4932-8 [11156254.001]

[Cites] Cancer Res. 2000 Dec 15;60(24):7133-41 [11156422.001]

[Cites] Anticancer Res. 2000 Nov-Dec;20(6B):4463-71 [11205289.001]

[Cites] Genes Chromosomes Cancer. 2001 Mar;30(3):316-21 [11170292.001]

[Cites] J Clin Oncol. 2001 Jan 15;19(2):448-57 [11208838.001]

[Cites] Biochem Pharmacol. 2001 Mar 1;61(5):573-8 [11239500.001]

[Cites] J Clin Oncol. 2001 Mar 15;19(6):1750-8 [11251006.001]

[Cites] Eur J Pharmacol. 2001 Mar 23;416(1-2):19-24 [11282108.001]

[Cites] Cancer. 2001 Apr 15;91(8):1494-9 [11301397.001]

[Cites] Lung Cancer. 2001 May;32(2):117-28 [11325482.001]

[Cites] Biochem Pharmacol. 2001 Jun 1;61(11):1401-8 [11331076.001]

[Cites] Cancer Res. 2001 May 15;61(10):3986-97 [11358816.001]

[Cites] Biochem Pharmacol. 2001 Jul 1;62(1):13-9 [11377392.001]

[Cites] Anticancer Res. 2009 Jul;29(7):2453-9 [19596913.001]

[Cites] Lung Cancer. 2009 Sep;65(3):377-82 [19150580.001]

[Cites] Mod Pathol. 2009 Sep;22(9):1139-50 [19525928.001]

[Cites] Cancer Res. 2009 Oct 1;69(19):7672-80 [19773430.001]

[Cites] Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6 [19805294.001]

[Cites] Mol Biol Rep. 2009 Nov;36(8):2099-109 [19107575.001]

[Cites] Lung Cancer. 2009 Nov;66(2):176-83 [19285749.001]

[Cites] Lung Cancer. 2009 Dec;66(3):298-304 [19324449.001]

[Cites] Chin Med J (Engl). 1999 Apr;112(4):336-9 [11593534.001]

[Cites] Clin Cancer Res. 2001 Oct;7(10):3239-50 [11595720.001]

[Cites] Semin Oncol. 2001 Aug;28(4 Suppl 14):37-44 [11605182.001]

[Cites] Ai Zheng. 2005 Dec;24(12):1510-3 [16351803.001]

[Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8872-9 [16361577.001]

[Cites] J Clin Oncol. 2005 Dec 20;23(36):9097-104 [16361616.001]

[Cites] J Clin Oncol. 2005 Dec 20;23(36):9105-12 [16361617.001]

[Cites] Mol Cancer Ther. 2005 Dec;4(12):2001-7 [16373715.001]

[Cites] Cancer. 2006 Jan 15;106(2):441-7 [16342067.001]

[Cites] Mol Carcinog. 2006 Feb;45(2):84-92 [16329146.001]

[Cites] Int J Cancer. 2006 Apr 1;118(7):1692-8 [16231322.001]

[Cites] Clin Cancer Res. 2006 Feb 15;12(4):1317-24 [16489089.001]

[Cites] Lung Cancer. 2006 Mar;51(3):303-11 [16406195.001]

[Cites] Biochem Pharmacol. 2006 Apr 14;71(8):1265-71 [16442503.001]

[Cites] Neoplasia. 2006 Jan;8(1):9-17 [16533421.001]

[Cites] J Pharm Pharmacol. 2006 Mar;58(3):327-36 [16536899.001]

[Cites] J Clin Oncol. 2006 Mar 20;24(9):1428-34 [16549837.001]

[Cites] J Chemother. 2006 Feb;18(1):66-73 [16572896.001]

[Cites] Jpn J Clin Oncol. 2006 Mar;36(3):137-41 [16478794.001]

[Cites] FEBS Lett. 2006 Apr 17;580(9):2258-64 [16579994.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6332-7 [16601104.001]

[Cites] Oncol Rep. 2006 Jun;15(6):1533-9 [16685392.001]

[Cites] Lung Cancer. 2006 Jun;52(3):343-7 [16574270.001]

[Cites] Lung Cancer. 2006 Jun;52(3):281-90 [16616798.001]

[Cites] Br J Cancer. 2006 May 22;94(10):1452-9 [16641908.001]

[Cites] Pharmacogenet Genomics. 2006 Jun;16(6):429-38 [16708051.001]

[Cites] J Clin Oncol. 2006 May 20;24(15):2237-44 [16636344.001]

[Cites] Cancer. 2006 Jun 1;106(11):2421-7 [16649224.001]

[Cites] Mol Cancer Ther. 2006 May;5(5):1154-65 [16731747.001]

[Cites] Oncogene. 2006 Jun 1;25(23):3335-45 [16462770.001]

[Cites] Zhonghua Zhong Liu Za Zhi. 2006 Feb;28(2):107-10 [16750013.001]

[Cites] Int J Cancer. 2006 Sep 1;119(5):1028-38 [16570272.001]

[Cites] Lung Cancer. 2006 Jul;53(1):103-9 [16716446.001]

[Cites] Int J Cancer. 2006 Jul 15;119(2):432-40 [16477640.001]

[Cites] Cancer Res. 2006 Jun 15;66(12):6353-60 [16778213.001]

[Cites] Jpn J Clin Oncol. 2006 Jun;36(6):344-50 [16818479.001]

[Cites] Am J Respir Cell Mol Biol. 2008 May;38(5):559-65 [18096875.001]

[Cites] Int J Oncol. 2008 May;32(5):1133-7 [18425342.001]

[Cites] Cancer Biol Ther. 2007 Dec;6(12):1858-66 [18087215.001]

[Cites] Int J Biol Markers. 2006 Apr-Jun;21(2):81-7 [16847810.001]

[Cites] Ann Nucl Med. 2006 May;20(4):269-75 [16856570.001]

[Cites] Zhonghua Zhong Liu Za Zhi. 2006 Mar;28(3):196-9 [16875604.001]

[Cites] Zhonghua Zhong Liu Za Zhi. 2006 Apr;28(4):253-6 [16875621.001]

[Cites] Int J Oncol. 2003 Apr;22(4):721-32 [12632061.001]

[Cites] Oncogene. 2003 Apr 10;22(14):2192-205 [12687021.001]

[Cites] Mol Cancer Ther. 2003 Apr;2(4):371-82 [12700281.001]

[Cites] Int J Cancer. 2003 Jul 1;105(4):472-9 [12712436.001]

[Cites] J Exp Clin Cancer Res. 2003 Mar;22(1):69-75 [12725325.001]

[Cites] Biochemistry. 2003 May 13;42(18):5349-57 [12731876.001]

[Cites] Toxicol Sci. 2003 Jun;73(2):294-300 [12700406.001]

[Cites] Oncogene. 2003 Jun 5;22(23):3548-53 [12789263.001]

[Cites] Br J Cancer. 2003 Jun 16;88(12):1963-70 [12799644.001]

[Cites] Cancer Res. 2003 Jun 15;63(12):3112-20 [12810637.001]

[Cites] Anticancer Res. 2003 Mar-Apr;23(2B):1207-12 [12820372.001]

[Cites] Cancer Sci. 2003 Apr;94(4):394-9 [12824911.001]

[Cites] Br J Cancer. 2003 Jul 7;89(1):55-64 [12838300.001]

[Cites] Cancer Invest. 2006 Oct;24(6):576-80 [16982461.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14513-8 [16983095.001]

[Cites] Br J Cancer. 2006 Oct 9;95(7):822-8 [16969346.001]

[Cites] Lung Cancer. 2006 Nov;54(2):235-40 [16934363.001]

[Cites] Lung Cancer. 2006 Nov;54(2):217-25 [16934364.001]

[Cites] Lung Cancer. 2006 Nov;54(2):135-42 [16965834.001]

[Cites] FEBS Lett. 2005 Dec 5;579(29):6681-7 [16307741.001]

[Cites] Cancer Res. 2006 Oct 1;66(19):9682-90 [17018626.001]

[Cites] J Clin Oncol. 2004 Mar 1;22(5):777-84 [14990632.001]

[Cites] J Clin Oncol. 2004 Mar 1;22(5):785-94 [14990633.001]

[Cites] Strahlenther Onkol. 2004 Mar;180(3):157-64 [14991204.001]

[Cites] J Clin Oncol. 2006 Oct 10;24(29):4731-7 [16966686.001]

[Cites] Genes Chromosomes Cancer. 2006 Dec;45(12):1094-105 [16967470.001]

[Cites] Mol Hum Reprod. 2006 Nov;12(11):661-9 [16954445.001]

[Cites] J Clin Oncol. 2006 Oct 20;24(30):4825-32 [17050867.001]

[Cites] Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006 Oct;31(5):717-22 [17062938.001]

[Cites] Stem Cells. 2006 Nov;24(11):2437-47 [16888285.001]

[Cites] Clin Cancer Res. 2006 Nov 15;12(22):6748-57 [17121895.001]

[Cites] J Nucl Med. 2006 Dec;47(12):1921-6 [17138734.001]

[Cites] Int J Oncol. 2007 Jan;30(1):187-92 [17143528.001]

[Cites] Arch Pharm Res. 2006 Nov;29(11):1018-23 [17146971.001]

[Cites] Zhonghua Zhong Liu Za Zhi. 2006 Jun;28(6):408-12 [17152483.001]

[Cites] Ann Oncol. 2006 Dec;17(12):1818-25 [16980606.001]

[Cites] Zhonghua Yi Xue Za Zhi. 2006 Oct 10;86(37):2611-4 [17198586.001]

[Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4905-9 [17214360.001]

[Cites] Breast Cancer Res. 2006;8(5):R59 [17062128.001]

[Cites] Cancer Chemother Pharmacol. 2007 Mar;59(4):507-13 [16896928.001]

[Cites] J Exp Ther Oncol. 2006;6(1):49-53 [17228524.001]

[Cites] J Thorac Cardiovasc Surg. 2007 Feb;133(2):303-8 [17258552.001]

[Cites] J Thorac Cardiovasc Surg. 2007 Feb;133(2):352-63 [17258563.001]

[Cites] Cancer Genet Cytogenet. 2007 Feb;173(1):1-9 [17284363.001]

[Cites] Clin Cancer Res. 2007 Feb 1;13(3):994-9 [17289895.001]

[Cites] Med Oncol. 2006;23(4):489-98 [17303907.001]

[Cites] Ann Oncol. 2007 Mar;18(3):447-52 [17082511.001]

[Cites] Clin Cancer Res. 2007 Mar 1;13(5):1540-51 [17332300.001]

[Cites] Eur J Pharm Biopharm. 2007 Mar;65(3):289-99 [17123800.001]

[Cites] Cancer Treat Rev. 2007 Apr;33(2):101-37 [17276603.001]

[Cites] Int J Cancer. 2007 May 1;120(9):2019-27 [17266043.001]

[Cites] Zhonghua Zhong Liu Za Zhi. 2006 Oct;28(10):750-2 [17366786.001]

[Cites] Exp Cell Res. 2007 Apr 1;313(6):1215-24 [17291493.001]

[Cites] J Thorac Oncol. 2006 Sep;1(7):679-83 [17409936.001]

[Cites] J Thorac Oncol. 2007 Apr;2(4):293-8 [17409800.001]

[Cites] Clin Cancer Res. 2007 Apr 15;13(8):2414-21 [17438100.001]

[Cites] J Clin Oncol. 2007 Apr 20;25(12):1545-52 [17442998.001]

[Cites] Mol Cancer Res. 2009 Mar;7(3):330-8 [19276181.001]

[Cites] J Chemother. 2009 Feb;21(1):86-90 [19297279.001]

[Cites] Nat Rev Mol Cell Biol. 2009 Apr;10(4):265-75 [19305416.001]

[Cites] J Thorac Oncol. 2007 May;2(5):423-9 [17473658.001]

[Cites] Cancer Res. 2007 May 1;67(9):4382-9 [17483352.001]

[Cites] Cancer Res. 2007 May 1;67(9):4425-33 [17483357.001]

[Cites] Clin Cancer Res. 2000 Dec;6(12):4885-92 [11156248.001]

[Cites] Int J Oncol. 2004 Aug;25(2):413-8 [15254739.001]

[Cites] Mol Cancer. 2003 Jan 3;2:1 [12537587.001]

[Cites] Mol Cancer. 2004 May 4;3:14 [15125777.001]

[Cites] Ann Oncol. 2004 Aug;15(8):1194-203 [15277258.001]

[Cites] Clin Cancer Res. 2004 Aug 1;10(15):4939-43 [15297394.001]

[Cites] Ai Zheng. 2004 Aug;23(8):963-7 [15301725.001]

[Cites] Ann Univ Mariae Curie Sklodowska Med. 2003;58(1):149-53 [15314975.001]

[Cites] Cancer Chemother Pharmacol. 2004 Oct;54(4):301-7 [15138708.001]

[Cites] J Mol Histol. 2004 Mar;35(3):255-62 [15339045.001]

[Cites] Lung Cancer. 2004 Oct;46(1):77-85 [15364135.001]

[Cites] Cancer Res. 2004 Sep 15;64(18):6359-62 [15374938.001]

[Cites] Hum Mol Genet. 2004 Oct 15;13(20):2443-9 [15317748.001]

[Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6086-93 [15447994.001]

[Cites] Clin Cancer Res. 2001 Jun;7(6):1798-804 [11410522.001]

[Cites] Oncol Rep. 2001 Jul-Aug;8(4):825-9 [11410792.001]

[Cites] Oncogene. 2001 May 24;20(23):2877-88 [11420700.001]

[Cites] Int J Cancer. 2001 Aug 15;93(4):584-9 [11477564.001]

[Cites] Int J Cancer. 2001 Aug 15;93(4):590-600 [11477565.001]

[Cites] Cancer. 2001 Aug 15;92(4):836-42 [11550155.001]

[Cites] Lung Cancer. 2001 Aug-Sep;33(2-3):115-23 [11551406.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11737-42 [11562465.001]

[Cites] Exp Cell Res. 2004 Aug 1;298(1):83-95 [15242764.001]

[Cites] Ai Zheng. 2004 Jul;23(7):845-50 [15248926.001]

[Cites] Br J Cancer. 2004 Jul 19;91(2):270-6 [15199393.001]

[Cites] Lung Cancer. 2001 Dec;34(3):427-32 [11714540.001]

[Cites] Lung Cancer. 2002 Jan;35(1):11-6 [11750707.001]

[Cites] Chin Med J (Engl). 2000 Oct;113(10):957-60 [11775848.001]

[Cites] Zhonghua Jie He He Hu Xi Za Zhi. 1999 May;22(5):268-70 [11775850.001]

[Cites] Zhonghua Zhong Liu Za Zhi. 1999 Nov;21(6):422-6 [11776616.001]

[Cites] Zhonghua Zhong Liu Za Zhi. 2000 Jul;22(4):304-7 [11778556.001]

[Cites] Oncogene. 2002 Jan 10;21(2):260-71 [11803469.001]

[Cites] Int J Cancer. 2002 Feb 10;97(5):584-92 [11807782.001]

[Cites] Ann Oncol. 2001 Nov;12(11):1561-6 [11822755.001]

[Cites] Lung Cancer. 2002 Mar;35(3):305-14 [11844606.001]

[Cites] Clin Sci (Lond). 2002 Apr;102(4):417-24 [11914104.001]

[Cites] Cancer. 2002 Mar 15;94(6):1808-14 [11920544.001]

[Cites] Cancer Res. 2002 Apr 1;62(7):1935-8 [11929805.001]

[Cites] J Cancer Res Clin Oncol. 2002 Mar;128(3):141-7 [11935300.001]

[Cites] Lung Cancer. 2002 May;36(2):159-65 [11955650.001]

[Cites] Ann Nucl Med. 2002 Apr;16(2):103-8 [12043903.001]

[Cites] Biochem Pharmacol. 2002 Jun 1;63(11):1989-96 [12093475.001]

[Cites] Eur J Nucl Med Mol Imaging. 2002 Jul;29(7):876-81 [12111127.001]

[Cites] Clin Cancer Res. 2002 Jul;8(7):2286-91 [12114432.001]

[Cites] Clin Cancer Res. 2002 Jul;8(7):2443-7 [12114451.001]

[Cites] Jpn J Cancer Res. 2002 Jul;93(7):816-24 [12149148.001]

[Cites] Br J Cancer. 2002 Aug 12;87(4):385-92 [12177774.001]

[Cites] Cell Death Differ. 2002 Sep;9(9):893-904 [12181740.001]

[Cites] Mol Pharmacol. 2002 Sep;62(3):689-97 [12181446.001]

[Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):237-44 [12182997.001]

[Cites] Cancer Invest. 2002;20(5-6):686-92 [12197224.001]

[Cites] J Biol Chem. 2002 Sep 20;277(38):35305-13 [12121973.001]

[Cites] Oncology. 2002;63(2):173-9 [12239453.001]

[Cites] Exp Cell Res. 2002 Oct 1;279(2):277-90 [12243753.001]

[Cites] Int J Oncol. 2002 Nov;21(5):1087-92 [12370759.001]

[Cites] Br J Cancer. 2002 Oct 7;87(8):924-32 [12373610.001]

[Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):895-902 [12377343.001]

[Cites] Eur Respir J. 2002 Oct;20(4):975-81 [12412692.001]

[Cites] Br J Cancer. 2006 Jul 17;95(2):139-45 [16786043.001]

[Cites] EMBO J. 2006 Jul 12;25(13):3078-88 [16810323.001]

[Cites] Cancer Lett. 2006 Aug 18;240(1):148-56 [16249053.001]

[Cites] J Liposome Res. 2002 Nov;12(4):301-9 [12519627.001]

[Cites] Int J Cancer. 2003 Mar 20;104(2):238-42 [12569581.001]

[Cites] Lung Cancer. 2003 Feb;39(2):139-43 [12581565.001]

[Cites] Respiration. 2003 Jan-Feb;70(1):32-5 [12584388.001]

[Cites] Nucl Med Biol. 2003 Aug;30(6):627-32 [12900288.001]

[Cites] Anticancer Res. 2003 May-Jun;23(3C):2829-36 [12926120.001]

[Cites] Am J Pathol. 2003 Sep;163(3):1109-16 [12937152.001]

[Cites] Lung. 2003;181(2):103-11 [12953149.001]

[Cites] Cancer Lett. 2003 Sep 10;199(1):99-105 [12963129.001]

[Cites] Br J Cancer. 2003 Sep 15;89(6):959-65 [12966408.001]

[Cites] Biochem Pharmacol. 2003 Oct 1;66(7):1207-18 [14505800.001]

[Cites] Med Oncol. 2003;20(3):247-53 [14514974.001]

[Cites] Int J Oncol. 2003 Nov;23(5):1333-9 [14532974.001]

[Cites] Tumour Biol. 2003 May-Jun;24(3):151-5 [14610319.001]

[Cites] Cancer Res. 2003 Nov 15;63(22):7891-9 [14633718.001]

[Cites] Lung Cancer. 2003 Dec;42(3):275-81 [14644514.001]

[Cites] Cancer Biol Ther. 2003 Nov-Dec;2(6):663-9 [14688473.001]

[Cites] Cancer Res. 2003 Dec 15;63(24):8592-5 [14695168.001]

[Cites] Int J Cancer. 2004 Feb 10;108(4):580-7 [14696123.001]

[Cites] Lung. 2003;181(5):267-73 [14705770.001]

[Cites] Cancer Gene Ther. 2003 Dec;10(12):898-906 [14712316.001]

[Cites] Oncol Rep. 2004 Feb;11(2):407-14 [14719076.001]

[Cites] J Thorac Cardiovasc Surg. 2004 Feb;127(2):365-75 [14762343.001]

[Cites] Clin Cancer Res. 2004 Feb 1;10(3):1080-9 [14871988.001]

[Cites] Clin Cancer Res. 2004 Feb 15;10(4):1318-25 [14977831.001]

[Cites] Cancer Res. 1990 Jan 15;50(2):304-9 [1967222.001]

[Cites] Cancer Res. 1990 May 1;50(9):2549-53 [2158392.001]

[Cites] Int J Cancer. 1990 Jul 15;46(1):138-44 [2163989.001]

[Cites] Br J Cancer. 1990 Jul;62(1):72-7 [2390486.001]

[Cites] Cancer Res. 1991 Jun 15;51(12):3237-42 [1645616.001]

[Cites] J Natl Cancer Inst. 1992 Jan 15;84(2):113-8 [1310509.001]

[Cites] Cancer Res. 1992 Apr 1;52(7):1666-74 [1312895.001]

[Cites] Semin Oncol. 1992 Jun;19(3 Suppl 9):94-100 [1641661.001]

[Cites] Acta Med Okayama. 1992 Jun;46(3):203-12 [1354408.001]

[Cites] Eur J Cancer. 1992;28A(8-9):1427-31 [1515264.001]

[Cites] Cytometry. 1992;13(4):416-22 [1526199.001]

[Cites] J Cancer Res Clin Oncol. 1992;119(1):28-34 [1400562.001]

[Cites] Anticancer Drugs. 1992 Aug;3(4):359-66 [1330082.001]

[Cites] Cancer Res. 1992 Dec 15;52(24):6885-9 [1458477.001]

[Cites] Cancer. 1993 Apr 1;71(7):2204-9 [8095847.001]

[Cites] Jpn J Clin Oncol. 1993 Feb;23(1):14-9 [8384671.001]

[Cites] Surg Today. 1993;23(3):193-9 [8467169.001]

[Cites] J Natl Cancer Inst. 1993 Jun 2;85(11):897-901 [8098377.001]

[Cites] Cancer Res. 1993 Jul 15;53(14):3302-7 [8391922.001]

[Cites] Cancer Chemother Pharmacol. 1993;32(4):315-9 [8324874.001]

[Cites] J Clin Oncol. 2002 Dec 1;20(23):4508-16 [12454106.001]

[Cites] Mol Cancer Ther. 2002 Sep;1(11):913-22 [12481412.001]

[Cites] Oncogene. 2002 Dec 12;21(57):8683-95 [12483521.001]

[Cites] Ann Thorac Surg. 2003 Jul;76(1):187-93; discussion 193 [12842538.001]

[Cites] Saudi Med J. 2003 May;24(5):493-8 [12847624.001]

[Cites] J Clin Oncol. 2003 Jul 15;21(14):2645-50 [12860939.001]

[Cites] Lung Cancer. 2003 Aug;41(2):199-206 [12871783.001]

[Cites] Antibiot Khimioter. 2003;48(10):11-5 [15004974.001]

[Cites] Clin Cancer Res. 2004 Mar 1;10(5):1691-7 [15014021.001]

[Cites] Mol Cancer Ther. 2004 Mar;3(3):223-32 [15026542.001]

[Cites] Mol Cancer Ther. 2004 Mar;3(3):327-34 [15026553.001]

[Cites] Zhonghua Yi Xue Za Zhi. 2004 Feb 17;84(4):323-8 [15059518.001]

[Cites] Lung Cancer. 2004 May;44(2):241-9 [15084389.001]

[Cites] EMBO J. 2004 Apr 21;23(8):1889-99 [15071501.001]

[Cites] Zhonghua Yi Xue Za Zhi. 2004 Apr 17;84(8):663-6 [15130309.001]

[Cites] Lung Cancer. 2004 Jun;44(3):311-6 [15140544.001]

[Cites] Cancer Lett. 2004 Jun 25;209(2):177-85 [15159020.001]

[Cites] Carcinogenesis. 2004 Jun;25(6):909-21 [14742324.001]

[Cites] Am J Clin Oncol. 2004 Jun;27(3):215-9 [15170136.001]

[Cites] Cancer Res. 2004 Jun 1;64(11):3761-6 [15172981.001]

[Cites] Clin Cancer Res. 2004 Jun 1;10(11):3639-49 [15173070.001]

[Cites] Br J Cancer. 2004 Jun 14;90(12):2370-7 [15150572.001]

[Cites] Ai Zheng. 2004 Jun;23(6):645-9 [15191663.001]

[Cites] Ai Zheng. 2004 Jun;23(6):667-71 [15191667.001]

[Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4215s-4219s [15217961.001]

[Cites] J Clin Oncol. 2004 Jul 1;22(13):2594-601 [15173214.001]

[Cites] J Inorg Biochem. 2004 Oct;98(10):1599-606 [15458822.001]

[Cites] Ann Thorac Surg. 2004 Oct;78(4):1207-14; discussion 1207-14 [15464472.001]

[Cites] Cancer Sci. 2004 Sep;95(9):753-7 [15471562.001]

[Cites] Int J Cancer. 2004 Dec 20;112(6):934-42 [15386349.001]

[Cites] J Exp Ther Oncol. 2004 Jul;4(2):155-60 [15500010.001]

[Cites] Cancer Chemother Rep. 1975 Jul-Aug;59(4):777-93 [1175169.001]

[Cites] J Pharmacol Exp Ther. 1977 Mar;200(3):469-78 [557542.001]

[Cites] J Natl Cancer Inst. 1981 Sep;67(3):663-9 [6944536.001]

[Cites] J Clin Oncol. 1983 Jan;1(1):17-23 [6422002.001]

[Cites] Gan To Kagaku Ryoho. 1985 Aug;12(8):1582-7 [3927847.001]

[Cites] Jpn J Cancer Res. 1988 Mar;79(3):301-4 [2836347.001]

[Cites] Cancer Treat Rev. 1989 Mar;16(1):1-40 [2659168.001]

[Cites] J Natl Cancer Inst. 1989 Jul 19;81(14):1069-75 [2544740.001]

[Cites] Cancer Res. 1989 Nov 1;49(21):5829-36 [2790794.001]

[Cites] Acta Oncol. 2007;46(3):361-6 [17450472.001]

[Cites] Lung Cancer. 2007 May;56(2):281-8 [17222938.001]

[Cites] Clin Cancer Res. 2007 May 1;13(9):2577-83 [17473186.001]

[Cites] Int J Cancer. 2004 Sep 10;111(4):484-93 [15239124.001]

(PMID = 20047843.001).

[ISSN] 1879-0461

[Journal-full-title] Critical reviews in oncology/hematology

[ISO-abbreviation] Crit. Rev. Oncol. Hematol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA016672-32; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / 5-P30 CA16672-32; United States / NCI NIH HHS / CA / P30 CA016672-32

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Antineoplastic Agents

[Other-IDs] NLM/ NIHMS168520; NLM/ PMC2888634